University of South Carolina

Scholar Commons
Theses and Dissertations
Fall 2020

The Role of HIV-1 Tat-Mediated Inhibition of the Dopamine and
Norepinephrine Transporters in the Neuropathology of HIV-1
Associated Neurocognitive Disorders
Matthew Strauss

Follow this and additional works at: https://scholarcommons.sc.edu/etd

Recommended Citation
Strauss, M.(2020). The Role of HIV-1 Tat-Mediated Inhibition of the Dopamine and Norepinephrine
Transporters in the Neuropathology of HIV-1 Associated Neurocognitive Disorders. (Doctoral
dissertation). Retrieved from https://scholarcommons.sc.edu/etd/6157

This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please
contact digres@mailbox.sc.edu.

The Role of HIV-1 Tat-mediated Inhibition of the Dopamine and Norepinephrine
Transporters in the Neuropathology of HIV-1 Associated Neurocognitive
Disorders
by
Matthew Strauss
Doctor of Pharmacy
University of South Carolina, 2015

Submitted in Partial Fulfillment of the Requirements
For the Degree of Doctor of Philosophy in
Pharmaceutical Sciences
College of Pharmacy
University of South Carolina
2020
Approved by:
Jun Zhu, Major Professor
Michael Wyatt, Committee Member
Doug Pittman, Committee Member
Kim Creek, Committee Member
David Mott, Committee Member
Cheryl L. Addy, Vice Provost and Dean of the Graduate School

© Copyright by Matthew Strauss, 2020
All Rights Reserved.
ii

DEDICATION
To my wife Caroline, without her encouragement, love, sacrifices, support, and
inspiration this work would not have been possible…

iii

ACKNOWLEDGEMENTS
First of all, I would like to express my utmost gratitude to my mentor, Dr.
Jun Zhu, whose mentorship has instilled in me an immeasurable respect for
science. In Dr. Zhu I have also found a great friend with whom I have shared
many laughs and had a multitude of great discussions about all aspects of life.
I am very grateful to all past and present members of the Zhu lab who
have become friends and colleagues, particularly Dr. Pam Quizon for being a
great friend and with whom I shared many memorable moments through the
years, I could not have succeeded without her mentorship and guidance. I would
also like to thank Dr. Wei-Lun Sun for his guidance and advice, as well as Sarah
Davis for taking the torch to lead the next group of young scientists in the Zhu
lab, I wish you the best of luck.
I also extend my gratitude to the members of my dissertation committee:
Drs. Kim Creek, Doug Pittman, Michael Wyatt, and David Mott for their invaluable
guidance and critiques. I would also like to thank Dr. Jay Mclaughlin for his
advice and friendship through both scientific and personal adventures.
Finally, I want to thank my family for their continued and unwavering
support throughout my academic career. To my parents, I only hope to be as
supportive to my growing family as you have been to me my entire life. To my
wife, Caroline, none of this would have been possible without you, and your
constant love and support means more than you could ever know.
iv

ABSTRACT
Despite the success of combinatorial antiretroviral therapy (cART) in
controlling peripheral HIV infection and improving the lives of HIV-1 patients,
roughly 50% of this population continues to develop a group of neurological
complications including cognitive dysfunction, motor deficits, and dementia
collectively referred to as HIV-associated neurocognitive disorders (HAND). The
continuing presence of the transactivator of transcription (Tat) protein in cARTtreated HIV-1 patients has been suggested to play a crucial role in the
neurotoxicity and cognitive impairment evident in HAND. HIV-1 Tat protein has
been detected in dopamine (DA) -rich brain areas, and long-term viral protein
exposure has been found to accelerate damage to the mesocorticolimbic DA
system. Previous reports from our laboratory indicate that HIV-1 Tat-mediated
damage to the dopaminergic system involves a direct allosteric interaction
between HIV-1 Tat and the DA transporter (DAT). Importantly, in the central
nervous system, in addition to the DAT, the norepinephrine (NE) transporter
(NET) is also responsible for maintaining DA homeostasis. Due to its high level of
homology with the DAT it is possible that HIV-1 Tat may induce DA dysregulation
through interactions with this transporter as well. Based on these findings, this
research project investigated the hypothesis that via direct inhibitory allosteric
interactions with the dopamine and norepinephrine transporters, the HIV-1 Tat
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protein dysregulates dopamine homeostasis, resulting in the neuropsychiatric
dysfunction prominently featured in HAND.
First, the possibility that HIV-1 Tat inhibition of DA uptake involves both
DAT and NET was investigated. Via site-directed mutagenesis of the
Tyrosine467 (Y467) residue of the NET to a phenylalanine (Y467F) or a histidine
(Y467H), which correlates with Tyrosine470 on the DAT, it was determined that
not only is HIV-1 Tat capable of inhibiting DA uptake through NET, but that this
interaction involved similar residues as the HIV-1 Tat/DAT interaction. Building
on this finding, the next step was to establish if HIV-1 Tat-mediated inhibition of
the DA and NE transporters could be replicated in an animal model of HAND.
Utilizing an inducible HIV-1 Tat transgenic mouse model (iTat-tg), it was
determined that HIV-1 Tat inhibited both the DA and NE transporters to a similar
extent in the prefrontal cortex (PFC) of the iTat-tg mice.
The critical question following these findings was if HIV-1 Tat-mediated
dysregulation of the dopaminergic system could be prevented, what effect would
this have on the development of cognitive deficits observed in HAND? This
possibility was investigated via generation of a mutant Tyrosine88 to
phenylalanine (Y88F) DAT mouse model, which was crossed with the iTat-tg
mouse. The Y88F DAT mutation proved capable of both preventing HIV-1 Tatmediated inhibition of the DAT in the PFC, as well as learning and memory
deficits which had been previously reported in the iTat-tg mice. These results
demonstrate that prevention of the HIV-1 Tat/DAT interaction is sufficient to
prevent DA dysregulation and associated neurocognitive deficits in HAND.
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Furthermore, this interaction is highlighted as a potential target for the
development of novel therapies which may serve as adjunct therapy to improve
the lives of HIV-1 infected patients.
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CHAPTER 1
INTRODUCTION

1.1 HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS
Untreated human immunodeficiency virus type 1 infection (HIV-1)
continually weakens the immune system of infected patients, ultimately
manifesting in the development of acquired immunodeficiency syndrome (AIDS)
(Vahlne 2009). Opportunistic infections, which are a direct consequence of the
development of AIDS, have decreased following the advent of combinatorial
antiretroviral therapy (cART) in the late 1990’s (Carpenter et al., 1996; Deeks et
al., 2013), transitioning HIV-1 infection from a terminal to a chronic diagnosis.
Due to the subsequent dramatic reduction in mortality, improvement in life
expectancy, and increased access to cART, the number of people living with
HIV-1 worldwide has steadily risen throughout the decades (Simioni et al., 2010;
Bonnet et al., 2013). Currently there are over 37 million people infected with HIV1 and nearly another 2 million are becoming infected each year (Figure 1.1).
These conditions have resulted in dramatically altered patient demographics, as
individuals over 50 years old now make up the largest percentage of the HIV-1
infected population (Centers for Disease Control and Prevention 2017). This shift
in patient demographics correlated with increased observation of a range of
neurological symptoms including cognitive dysfunction, behavioral changes,
1

Figure 1.1 Current state of the HIV-1 pandemic. Each point represents data from
a single year from the Institute for Health Metrics and Evaluation (IHME). The
green line represents the number of people currently infected with HIV-1
worldwide (x10), the red line represents new infections in that year, and the blue
line represents the number of deaths caused by HIV-1 infection in that year.
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motor deficits, and dementia which are collectively referred to as HIV-associated
neurocognitive disorders (HAND).
The first reports of HAND were described as early as the 1980’s, with the
only well-defined neurological complication of HIV-1 being HIV-associated
dementia (HAD) (Sanmarti et al., 2014). Since this time, evidence indicates a
shifting pattern of the neurocognitive impairment observed in HIV-1 patients, from
deficits in motor ability, the speed of information processing, and verbal speed in
the pre-cART era to deficits in memory and executive function in the post-cART
era (Heaton et al., 2011). In 2007, the Frascati Criteria was introduced, which
revised the HAND classification system into a spectrum of neurocognitive
disorders ranging from the very mild to the most severe (Figure 1.2) (Antinori et
al., 2007; Mind Exchange Working Group et al., 2013). The mildest stage of
HAND, Asymptomatic Neurocognitive Impairment (ANI), affects about 33% of
HIV-1 infected patients and is characterized by neuropsychological impairment in
at least two cognitive domains without affecting daily living. The next level, Mild
Neurocognitive Disorder (MND), affects 20-30% of HIV-1 infected patients and is
defined as mild to moderate impairment in at least two cognitive domains with a
disruption in activities of daily living. The most severe form, HAD, affects
between 2-8% of HIV-1 infected patients and is classified by cognitive
impairment in at least two cognitive domains and accompanied by significant
impairment of daily living. The diagnosis of HAND emphasizes that there must be
no evidence of cognitive impairment that does not have HIV-1 as the underlying
cause (Mind Exchange Working Group et al., 2013).

3

Figure 1.2 Classification of HIV-1 associated neurocognitive impairments.
Asymptomatic neurocognitive impairment (ANI) and is characterized by
neuropsychological impairment in at least two cognitive domains without affecting
daily living. The next level, Mild Neurocognitive Disorder (MND), affects 20-30%
of HIV1- infected patients and is defined as mild to moderate impairment in at
least two cognitive domains with a disruption in activities of daily living. The most
severe form, HAD, affects between 2-8% of HIV-1 infected patients and is
classified by cognitive impairment in at least two cognitive domains and
accompanied by significant impairment of daily living. Adapted from
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The development of HAND results, in part, because most cART
medications cannot cross the blood-brain barrier (BBB). In contrast, the HIV-1
virus is capable of bypassing the BBB by piggybacking on infected monocytes
and lymphocytes that migrate into the CNS (Clements et al., 2002; Orandle et al.,
2002; Williams et al., 2014), leaving it as a reservoir for HIV-1 viral replication
(Gray et al., 2014). Once in the CNS, infected monocytes mature into HIV-1
infected perivascular macrophages that produce virions and facilitate the spread
of the virus through production of neurotoxic viral particles, proteins, and
cytokines (Albright et al., 2003; Brown et al., 2006). This production facilitates
continued infection, neurotoxicity, and subsequent neuronal injury which are
central to the development of HAND (Thompson et al., 2011; Desplats et al.,
2013).
Because there is currently no treatment for HAND, the patient and
healthcare burden of these disorders will continue to rise, as estimates have
suggested that the number of HIV-1 patients with HAND will increase from 5- to
10-fold by the year 2030 (Cysique et al., 2011). Thus, novel therapeutics, which
are capable of preventing HAND in the early stages of HIV-1 infection, will greatly
enhance HIV-1 infected patients’ quality of life as well as the economic burden on
the healthcare system.
1.2.1 HIV-1 VIRAL PROTEINS
The HIV-1 virus is composed of at least nine genes which are flanked by a
long terminal repeats (LTRs). These genes code for specific proteins which can
be classified into three distinct categories: (1) the major structural proteins – Gag,
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Pol, and Env; (2) regulatory proteins – Tat and Rev; and (3) accessory proteins –
Vpu, Vpr, Vif, and Nef (Gallo et al., 1988). Each of these proteins has distinct
functions which are required at various stages of the virus’ life cycle.
Structural proteins
The gag gene gives rise to the 55-kilodalton Gag precursor protein (p55),
which is expressed from the unspliced viral mRNA. Following post-translational
modifications, the membrane-associated Gag polyprotein triggers the budding of
the viral particle from the surface of an infected cell. After budding, p55 is
cleaved by the virally encoded protease (a product of the pol gene) into four
smaller proteins: matrix (p17) – facilitates nuclear transport of the viral genome;
capsid (p24) – forms the conical core of the viral particle; nucleocapsid (p9) –
recognizes packaging signals and helps in reverse transcription; and p6 – which
aids in the interaction of p55 and vpr, as well as the release of viral particles from
infected cells (Göttlinger et al., 1989; King, 1994; Lee et al., 2012). The Gag and
Pol genes are initially expressed as a single precursor protein (p160). p160 is
generated by a ribosomal frame shifting event, which is triggered by a specific
cis-acting RNA motif (Parkin et al., 1992). During viral maturation, the virally
encoded protease cleaves the Pol polypeptide away from Gag and further
digests it into four separate enzymes: reverse transcriptase – transcribes DNA
from the RNA template; RNase H – facilitates complementary DNA strand
synthesis by cleaving the original RNA template; integrase – required for
integration of proviral DNA into the host genome; and protease – involved with
cleaving of the p55 protein (Lee et al., 2012). Env (envelope) migrates through
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the Golgi complex where it undergoes glycosylation, which is required for
infectivity (Capon et al., 1991). A cellular protease cleaves Env (gp160) to
generate gp41 and gp120. gp41 contains the transmembrane domain of Env,
and serves as an anchor for the viral envelope, while gp120 mediates HIV-1
infection through interactions with the CD4 receptor that is present on
lymphocytes (King, 1994; merk and Subramaniam, 2013).
Regulatory proteins
Tat (trans-activator of transcription) is essential for HIV-1 viral replication
Ruben et al., 1989) and acts as an RNA binding protein, binding to a short-stem
loop structure, known as the transactivation response element (TAR), that is
located at the 5’ terminus of HIV RNAs (Ruben et al., 1989; Feinberg et al.,
1991). The Tat protein is discussed in further detail below. Rev (regulator of
expression of virion proteins) in another RNA-binding protein. Rev binds to the
Rev response element (RRE) within the second intron of the HIV-1 genome and
is essential to activate late genes and for the synthesis of viral proteins to
produce virions (Zapp and Green, 1989; Vercruysse and Daelemans, 2014).
Accessory proteins
The accessory proteins are not absolutely required for viral replication in
all in vitro systems but represent critical virulence factors in vivo. Nef, Vif, Vpr,
and Vpu have multifaceted activities that are mostly involved in the evasion of
innate and adaptive immune systems. Specifically, Nef and Vpu are capable of
manipulating the localization and functional aspects of host cell membrane
proteins, facilitating viral entry (Miller et al., 1994). Vif and Vpr protect the virus by
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inhibition of cytoplasmic host defense molecules and by modifying the host cell
intracellular environment. The effects of the accessory proteins greatly influence
viral replication and aid the virus in escaping the host immune system.
1.2.2 HIV-1 TAT PROTEIN
Of the aforementioned HIV-1 viral proteins, the HIV-1 Tat protein has been
one of the most well studied in the context of HAND pathology (Gaskill et al.,
2017; Zhu et al., 2018), and the reasons for our specific focus on this viral protein
are twofold. The first is that HIV-1 Tat protein has been detected in the plasma,
serum, and cerebrospinal fluid (CSF) of HIV-1 infected patients (Westendorp et
al., 1995; Xiao et al., 2000). The levels of HIV-1 Tat in the plasma and CSF have
been reported to be in the low nanomolar range, however, the authors
(Westendorp et al., 1995; Xiao et al., 2000) argued that these concentrations
may be lower than the actual concentration present in the system due to the
close proximity of HIV-1 infected cells in the brain (Hayashi et al., 2006).
Regardless of the exact concentration of HIV-1 Tat in the CNS, the second
reason for the focus on this viral protein is due to its potent neurotoxicity
(Sabatier et al., 1991; King et al., 2006). Specifically, the continued presence of
HIV-1 Tat in cART-treated HIV-1 patients (Johnson et al., 2013; Henderson et al.,
2019) has been suggested to play a critical role in the cognitive impairment
evident in HAND (Rappaport et al., 1999; King et al., 2006).
HIV-1 Tat is a small (86 amino acid) nonstructural polypeptide composed
of six protein domains that are encoded by two exons (Figure 1.3). Amino acids
1-72 represent the first five domains and are encoded from the first exon, which
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Figure 1.3 HIV-1 trans-activator of transcription protein organization. Amino
acids 1-21 (blue) indicate the acidic/proline-rich domain, 22-37 (red) the cysteinerich domain, 38-48 (orange) the hydrophobic core domain, 48-57 (yellow) the
basic/arginine-rich domain, and 58-72 (green) the glutamine-rich domain. The
second axon (carboxyl terminus) varies in length and can be found in both 73-86
(Tat1-86) or 73-101 (Tat1-101) variants. Adapted from Gaskill et al., 2017.
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is critical to the transcriptional activity of HIV-1 Tat. These domains consist of an
acidic domain (residues 1-21), a cysteine-rich domain (residues 22-37), the
hydrophobic core domain (residues 38-48), a basic domain (residues 48-57), and
a glutamine-rich domain (residues 58-72). The sixth domain is a C-terminus
domain which varies in length (Bertrand et al., 2013), resulting in two HIV-1 Tat
variants: the 101 amino acid variant (Tat1-101), which represents the major variant
isolated from HIV-1 clinical samples, and the 86 amino acid variant (Tat 1-86),
which is primarily utilized for research purposes (Gaskill et al., 2017). Importantly,
studies comparing the two variants have shown no marked differences between
these types (Ma and Nath 1997; Bertrand et al., 2013; Midde et al., 2013). The
studies reported in this dissertation utilized the Tat1-86 variant.
In the CNS HIV-1 Tat is secreted by HIV-1 infected macrophages and
microglia and is subsequently absorbed into uninfected cells (Frankel and Pabo
1988; Vivès et al., 1997; Frankel and Young 1998). HIV-1 Tat has been found to
have various neurotoxic effects, including but not limited to activation of dormant
T-lymphocytes (Ott, 1997), induction of cellular apoptosis (Li et al., 1995;
Westendorp et al., 1995), modulation of gene expression via disruption of
intracellular signaling cascades (Westendorp et al., 1995; Nath and Geiger 1998;
Jeang et al,. 1999), and increasing BBB permeability (Toborek et al., 2005).
Furthermore, HIV-1 Tat has been detected in dopamine (DA) rich brain areas
(Del Valle et al., 2000; Hudson et al., 2000; Lamers et al., 2010) and where it
perturbs the dopaminergic system, which has been implicated in the
neuropathology of HAND (Purohit et al., 2011; Wang et al., 2004; Gaskill et al.,
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2017; Zhu et al., 2018). The effects of HIV-1 Tat on the dopaminergic system in
the context of HAND is discussed in detail in the following section.
1.3 HIV-1 TAT AND THE DOPAMINERGIC SYSTEM
1.3.1 Role of dopamine in the central nervous system
Dopamine (DA) plays a crucial role in multiple CNS functions, including
but not limited to motor control, reward, cognition, executive function, and
maternal behavior (Beaulieu and Gainetdinov, 2011; Klanker et al., 2013;
Nieoullon, 2002; Nutt et al., 2015). The majority of DA neurotransmission occurs
within four known pathways: the nigrostriatal pathway, the tuberoinfundinbular
pathway, and the mesolimbic and mesocortical pathways. This dissertation
focuses primarily on brain regions which are involved in the mesolimbic and
mesocortical pathways (the prefrontal cortex (PFC) and striatum), as these
pathways are frequently associated with reward-related cognition and executive
functions (Ikemoto, 2010), which are often affected in HAND. In the CNS, DA is
synthesized in dopaminergic and adrenergic neuron terminals, where the
conversion of L-tyrosine to L-DOPA, the precursor of DA, by tyrosine hydroxylase
is the rate-limiting step (Flatmark, 2000; Hornykiewicz, 2002). Once synthesized,
DA can be released via two distinct mechanisms, classical vesicular release and
DA transporter (DAT)- mediated efflux (Goodwin et al., 2009; Wall et al., 1995).
Following release, DA may either bind to post-synaptic receptors, be
metabolized, or, most frequently, be transported back into the pre-synaptic
terminal via DAT-mediated reuptake (Figure 1.4) (Eisenhofer et al., 2004).
Importantly, DA may also be transporter back into the pre-synaptic terminal by
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Figure 1.4 Representation of pre-synaptic dopaminergic terminal. In the presynaptic terminal dopamine (DA) can is stored in synaptic vesicles which, upon
action potential firing, are released into the synaptic cleft. In the synaptic cleft DA
can either bind to post-synaptic receptors, be metabolized by enzymes or glia
cells, or, most frequently, be transported back into the pre-synaptic cytosol by the
dopamine (DAT) or norepinephrine (NET) transporters. Once in the pre-synaptic
cytosol, DA is repackaged into synaptic vesicles via the vesicular monoamine
transporter (VMAT-2).
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the norepinephrine (NE) transporter (NET), in brain areas with low levels of DAT
expression, particularly the PFC (Morón et al., 2002). The specific effects of HIV1 on transporter function are discussed in detail in section 1.5 of this dissertation.
1.3.2 HIV-1 Tat and dopaminergic neurotransmission
HIV-1 Tat has been shown to be neurotoxic to a wide variety of
components of the CNS, each of which may play a role in the development of
HAND symptoms. However, due the strong evidence linking HIV-1 to
dysregulation of the dopaminergic system, and the evident impact of this
dysregulation in the development of HAND, this dissertation focuses solely on
the effects of HIV-1 on the dopaminergic system, although future studies
investigation the effects of HIV-1 Tat on other CNS systems will be beneficial to
uncover alternate potential mechanisms of this viral protein in the pathology of
HAND.
Studies utilizing both human subjects and animal models have
demonstrated that HIV-1-mediated damage to the dopaminergic system occurs
early in HIV-1 infection, often while patients are still asymptomatic (Lopez et al.,
1999; Koutsilieri et al, 2002b; Scheller et al., 2005). This damage has been
identified in both cART naïve (Kieburtz et al., 1991; Berger et al., 1994; Sardar et
al., 1996) and cART treated patients (Kumar et al., 2009, 2011; Scheller et al.,
2010; Horn et al., 2013), highlighting the pressing need to address these
pathologic observations. In vitro studies have found that increased levels of DA
may enhance viral replication in infected lymphocytes and macrophages
(Scheller et al., 2000; Koutsilieri et al., 2002), promoting oxidative stress which
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subsequently causes neuronal death. This effect creates a vicious cycle by which
dopaminergic

dysfunction

spurs

greater

infection,

thereby

enhancing

dopaminergic damage (Gaskill et al., 2017). As noted in the previous section,
there are multiple connections of dopaminergic neurons in throughout the brain,
with the striatum, ventral tegmental area (VTA), and PFC representing the most
clinically relevant regions. Interestingly, despite resembling each other in many
respects, dopaminergic neurons in these regions mediate distinct functions and
exhibit dissimilar responses to toxins and addictive agents (Choi et al., 2015; Teo
et al., 2004). It is currently unclear whether HIV-1 Tat protein differentially affects
these distinct regions, and this topic has been of particular interest in the context
of HIV-1 infection. For example, a recent study found that HIV-1 Tat expression
in a mouse model produced excitatory effects in medial prefrontal cortical
pyramidal neurons but was inhibitory in hippocampal pyramidal neurons (Cirino
et al., 2020). This selective vulnerability has also been found in the dopaminergic
system, where HIV-1 Tat exposure selectively decreased tyrosine hydroxylase
immunoreactivity in the substantia nigra but not in the VTA (Miller et al., 2018).
Studies such as this highlight the need for region-specific investigations into the
effects of HIV-1 Tat on the CNS, which may aid in identifying the underlying
molecular mechanisms of disease-related pathology.
The neurotoxic effects of HIV-1 Tat were first described using
neuroblastoma cells (Sabatier et al., 1991), which, although these cells are not
dopaminergic, provided an initial picture of the interaction between HIV-1 Tat and
neurons. Specifically, studies utilizing HIV-1 Tat exposed cultured human fetal
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neurons and microinjection of HIV-1 Tat into striatal neurons demonstrated that
HIV-1 Tat promotes neurotoxicity by triggering inflammatory cascades that
eventually induce neuronal death by apoptosis (New et al., 1997; Jones et al.,
1998; Zauli et al., 2000; Aksenov et al., 2001). Moreover, direct application of
HIV-1 Tat on dopaminergic neurons increases intracellular calcium levels,
thereby activating caspases and the subsequent generation of reactive oxygen
species (Kruman et al., 1998; Bonavia et al., 2001; Haughey and Mattson, 2002;
Mattson et al., 2005). Furthermore, an in vivo microdialysis study found
compromised DA levels in the striatum of HIV-1 Tat treated animals (Ferris et al.,
2009b) and HIV-1 Tat protein contributes to alterations in expression levels of
dopaminergic markers including tyrosine hydroxylase and dopamine receptor-1
(Zauli et al., 2000; Silvers et al., 2006; Silvers et al., 2007). As HIV-1 Tat has
been detected in DA-rich brain areas (Del Valle et al., 2000; Hudson et al., 2000;
Lamers et al., 2010), and antibodies against HIV-1 Tat have been found to
inversely correlate with HAND progression (Bachani et al., 2013), continued
investigation

into

the

precise

molecular

mechanisms

resulting

in

the

aforementioned neurotoxic effects of HIV-1 Tat on the dopaminergic system are
critical to the development of novel therapeutics which may prevent or delay
HAND progression.
1.3.3 Animal models of HAND
To understand the onset of disease related neuropathology and
progression, as well as to develop and test adjunctive therapies along with
antiretroviral drugs, animal models for HAND have proven extremely useful.
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Ideally, non-human primates such as chimpanzees would be utilized to mimic
HIV-1 infection and disease given their genetic similarity to humans (Van
Maanen and Sutton, 2003). However, due to financial considerations,
maintenance, difficulty in obtaining sufficient numbers to achieve statistically
significant outcomes and public apprehensions, their use has been limited in
HAND research. In contrast, rodent models have been extensively utilized to
study HIV-1 and associated neurologic dysfunction in spite of the challenges to
model disease associated with the species-specific nature of HIV-1 infection.
These models offer several advantages such as low cost, easy maintenance,
and a well characterized genome that can be exploited to alter a particular cell or
region of interest (Gorantla et al., 2012). These models have been created by
employing several approaches including stereotaxic injection of viral proteins
directly into the brain, expressing viral transgenes in animals, and transplantation
of infected human cells into immunodeficient rodents (Van Duyne et al., 2009;
Barreto et al., 2014).
One specific rodent model which has been utilized is the HIV-1 transgenic
(HIV-1 Tg) rat, which was developed by Reid et al., (2001). This model is derived
from the Fisher344/ BHsd rat strain and carry proviral DNA that is devoid of Gag
and Pol genes, making this model noninfectious. These mice display immune,
motor, and behavioral abnormalities similar to HAND patients (Reid et al., 2001).
Deficits in learning and cognition associated with asymptomatic HIV-1 infection
have been reported in these animals (Vigorito et al., 2007; Lashomb et al., 2009).
Furthermore, these animals demonstrate alterations in dopaminergic function,
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neuroinflammation, as well as deficits in several synaptic proteins (Persidsky and
Fox, 2007; Webb et al., 2010; Rao et al., 2011; Zhu et al., 2016). Despite the
utility of this model in the study of HAND neuropathology, it does have several
drawbacks. First, because this model expresses seven HIV-1 viral proteins, it is
impossible to determine the specific mechanisms of a single viral protein, and
second, because the viral proteins are expressed from birth it does not allow for
the determination of dose- and duration-dependent effects of these viral proteins.
Thus, while the HIV-1 Tg rat model allows for investigation of the overarching
neuropathological alterations observed in HAND, models which allow for precise
and controlled expression of single viral proteins may prove more useful in
discovering the precise mechanisms underlying HAND neuropathology.
One such model is the inducible HIV-1 Tat transgenic mouse model (iTattg) which was first described by Kim et al., (2003), and is utilized in chapters 3
and 4 of this dissertation. This model possesses a “tetracycline-on (TETON)”
promoter that becomes transcriptionally active when a tetracycline (in this case
doxycycline, Dox) is present. In these mice the TETON promoter is coupled to an
HIV-1 Tat protein coding gene, and thus HIV-1 Tat expression may be induced
by the administration of Dox. This TETON/HIV-1 Tat system is integrated into the
regulator for the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter,
which confers brain specific expression of HIV-1 Tat protein. Importantly,
although inducible expression of HIV-1 Tat in this model is not equivalent to
human HIV-1 infection and does not induce the same host response, this model
recapitulates many aspects of the neuropathologies and neurocognitive
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impairments observed in HIV-1 infected individuals (Kim et al., 2003).
Specifically, these mice demonstrate learning and memory impairments (Carey
et al., 2012), increased anxiety-like behavior (Paris et al., 2013), gray matter
density reductions (Carey et al., 2013), and altered cocaine-mediated
psychostimulation (Paris et al., 2014). Due to the potential for precise and
controlled expression of HIV-1 Tat protein in this model (Carey et al., 2012) it
offers specific advantages to investigate the precise molecular mechanisms
underlying HIV-1 Tat-mediated dysregulation of the dopaminergic system.
1.4 THE DOPAMINE AND NOREPINEPHRINE TRANSPORTERS
1.4.1 The neurotransmitter: sodium symporter family
Neurotransmitter: sodium symporters (NSSs) play an essential role in the
nervous

system

by

terminating

synaptic

transmission

and

recycling

neurotransmitters for reuse (Rudnick, 2002). NSSs are members of the solute
carrier 6 (SLC6) family of transporters including the DA, NE, serotonin, and
GABA transporters and are comprised of around 600-800 amino acids in their
primary sequence. These transporters possess 12 transmembrane (TM) helices
which display significant sequence identities (~50-70%) even amongst NSSs that
transport diverse substrates (Kristensen et al., 2011). Intracellular amino and
carboxyl termini help to control uptake and substrate recognition via multiple
putative post-translational modification sites (Foster et al., 2002; Fog et al., 2006;
Wu et al., 2015), although the variations in amino acid sequence between
transporters does result in distinct properties (Wang et al., 2015). NSSs are
secondary active transporters that utilize the Na+ gradient across the plasma
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membrane to catalyze the uptake of a variety of neurotransmitters from the
extracellular milieu against their concentration gradient in a cotransport
mechanism (Torres et al., 2003). Active substrate translocation follows an
alternating access model (Jardetzky, 1966; Yamashita et al., 2005). This model
suggests that substrate translocation is a dynamic process which requires
conformational transition between an outward, occluded, and inward facing
states.
Both the DA and NE transporters are capable of translocating DA in
distinct brain regions, and therefore spatial and temporal modulation of DA
signaling in the brain is dependent upon regulation of both of these transporters.
DAT- and NET-mediated behavioral and physiological function are dynamically
controlled by a variety of signaling cascades, macromolecules, and exogenous
factors (Joseph et al., 2019). Despite the lack of a complete understanding of
DAT and NET regulation in the CNS, a multitude of research suggests that
affecting molecules achieve their function through ligand-transporter interactions,
trafficking, post-translational modifications, and protein-protein interactions
(Navratna et al., 2018). For example, several studies have implied that synthetic
compounds

like

N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine

(SoRI-

20041) as well as point mutations at specific residues on the DAT cause subtle
alterations in transporter conformation which in turn have differential effects on
inward transport and efflux properties (Guptaroy et al., 2009; Rothman et al.,
2009). For the purposes of this dissertation, I will focus specifically on the
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allosteric regulatory mechanism which is relevant to the interaction between HIV1 Tat protein and the DA and NE transporters.
1.4.2 Allosteric dependent regulation
Molecular dynamics and simulation studies provided initial evidence for
the existence of an allosteric binding site for DA, a modulatory binding site on the
transporter that is topographically distinct from the primary binding site (Shi et al.,
2008; Shan et al., 2011). These studies suggest that direct interaction of ligands
and ions at allosteric binding sites may elicit progressive rearrangements in
transporter structure, shifting the conformational state in order to transport
substrate DA. Although the discovery of biological ligands which interact with this
allosteric site remain elusive, DAT/NET ligands including tricyclic antidepressants
and selective reuptake inhibitors have been shown to interact with this allosteric
binding site (Zhou et al., 2007; Zhou et al., 2009; Cheng and Bahar, 2019).
Synthetic compounds which interact with allosteric binding sites have also been
developed (Pariser et al., 2008). The synthetic compounds utilized in this study
(including SoRI-20041) inhibit the binding of [125I]3beta-(4’-iodophenyl) tropan2beta-carboxylic acid methyl ester ([125I]RTI-55) to the substrate binding site by
following allosteric inhibitory patterns. This was indicated by the finding that these
synthetic compounds do not follow the classical dose-dependent competitive
inhibition paradigm irrespective of the concentration of [125I]RTI-55. These
modulators also slowed the dissociation rate of pre-bound [125I]RTI-55 and
presented a decrease in Bmax and an increase in Kd values for [125I]RTI-55
binding, verifying the allosteric binding of these 4-quinazolinamine derivatives.
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Taken together, these findings demonstrate that various ligands may
allosterically modulate local rearrangements in the structural elements of NSS
transporters, which ultimately contribute to a functionally unique conformation of
the transporter.
1.5 HIV-1 TAT AND DOPAMINE TRANSPORTER FUNCTION
Within the last decade there has been significant interest in describing the
effects of HIV-1 Tat on DAT activity (Midde et al., 2013, 2015; Zhu et al., 2016;
Yuan et al., 2015a, 2016; Bucci, 2015). While these and other recent studies
suggest HIV-1 Tat may modulate DAT function, technical limitations such as the
lack of available HIV-1 Tat specific antibodies and the large amount of HIV-1 Tat
used in the studies limits interpretation (Gaskill et al., 2017). Despite these
limitations, these studies suggest the effects of HIV-1 infection on the
dopaminergic system may, at least in part, be mediated by HIV-1 Tat specific
effects on DAT function (Figure 1.5) (Chang et al., 2008; Maragos et al., 2003;
Perry et al., 2010; Wang et al., 2004). HIV-1 infected patients with dementia have
decreased DAT levels compared to both healthy controls as well as those with
HIV who do not have dementia (Wang et al., 2004). Specifically, the loss of DAT
molecules is most apparent in the caudate and putamen, similar to Parkinson’s
disease and other frontal-striatal pathologies (Itoh et al., 2000). Several studies
have reported that HIV-1 Tat, in the absence of viral replication, may negatively
affect dopamine transmission by targeting DAT activity, without affecting total
DAT levels in striatal homogenates (Aksenova et al., 2006; Wallace et al., 2006;
Zhu et al., 2009), although changes in cellular distribution of DAT were not
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Figure 1.5 Dopamine transporter and receptor expression in the context of HIV-1
associated dementia. Distribution volume ratio images of PET with [C 11]cocaine
(dopamine transporter, top row) and [C11]raclopride (dopamine receptor, bottom
row) in a 47-year-old control subject (left), a 48-year-old no dementia subject
(middle), and a 52-year-old HAD subject (middle), at the level of the basal
ganglia. The images are scaled with respect to the maximum value obtained in
the control subject and presented using the rainbow scale (red color = high value,
violet = low value). Adapted from Wang et al., 2004.
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examined in these studies. A study by Midde et al., (2012) examined this
phenomenon and suggested that HIV-1 Tat may induce DAT internalization via a
protein kinase C (PKC) dependent mechanism. Furthermore, given the relatively
high percentage of HIV-1 infected patients who abuse psychostimulants (Beyrer
et al., 2010; Mathers et al., 2008), and that these psychostimulants may impact
DAT trafficking (Holton et al., 2005; Hong and Amara, 2013; Mortenson et al.,
2008), a careful critical mechanistic information on how HIV-1 Tat regulates
dopamine neurotransmission.
Surface

plasmon

resonance

analysis

performed

in

rat

striatal

synaptosomes suggests that HIV-1 Tat directly interacts with DAT in a
concentration-dependent manner (Zhu et al., 2009). Further investigation into this
interaction using a computational modeling and experimental validation approach
has aided in characterization of the direct allosteric interaction between HIV-1 Tat
and DAT (Midde et al., 2013; 2015a; Yuan et al., 2015; Yuan et al., 2016; Quizon
et al., 2016; Sun et al., 2019). These studies suggest HIV-1 Tat may stabilize the
inward facing conformation of DAT, limiting the availability of extracellular DA
binding sites on the transporter, thereby attenuating DA uptake.
1.6 RESEARCH OBJECTIVES
The overarching hypothesis of this dissertation was that via direct
inhibitory allosteric

interactions with

the

dopamine

and

norepinephrine

transporters, the HIV-1 Tat protein dysregulates dopamine homeostasis,
resulting in the neuropsychiatric dysfunction prominently featured in HAND.
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Chapter 2 builds upon previous work demonstrating that HIV-1 Tat inhibits
DAT-mediated DA uptake via a direct allosteric interaction with specific residues
on the DAT. Due to the high level of homology between the DA and NE
transporters, including that several of the residues determined to be involved in
the HIV-1 Tat/DAT interaction are identical between DAT and NET, I
hypothesized that the inhibitory interaction between HIV-1 Tat and DAT extends
to the NET. I investigated this hypothesis by performing a single point mutation at
Tyrosine467 (Y467) on the NET to a phenylalanine (Y467F) or a histidine
(Y467H). These mutants were evaluated to determine their effects on the
functional and kinetic properties of the NET as well as for their potential role in
the HIV-1 Tat/NET interaction.
Chapter 3 utilized the inducible HIV-1 Tat transgenic mouse model (iTattg) which was described earlier in this chapter. The primary objective of the
research outlined in chapter 3 was to determine if the inhibitory effects of HIV-1
Tat on DAT and NET function could be replicated in an in vivo model of HAND.
Furthermore, we sought to determine if this inhibition would result in global
aberrations in the dopaminergic system, or if the effects of HIV-1 Tat on the
dopamine system would be observed in a region-specific manner.
Chapter 4 utilized an approach that combined previous in vitro findings as
well as those identified in Chapter 3 to determine what affect attenuation of HIV-1
Tat mediated inhibition of DAT function would have on behavioral outcomes
associated with HAND. To this end, a mutant DAT mouse model was generated
which possesses a Tyrosine88 to phenylalanine mutation (Y88F). This mutation
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was previously shown to attenuate the inhibitory effects of HIV-1 Tat on DAT in
vitro. These mice were evaluated to determine if this mutation had any effects on
basal transporter function or behavior. Finally, the Y88F DAT mutant mice were
crossed with the iTat-tg mice, allowing the Y88F DAT mutant mice to biologically
express HIV-1 Tat. We investigated the effects of the Y88F DAT mutation on the
findings reported in Chapter 3, as well as on previously reported cognitive deficits
observed in the iTat-tg mice.
Overall, the research outlined in this dissertation aims to clarify the
mechanism and role of HIV-1 Tat-mediated dysregulation of the dopaminergic
system in the context of HIV-1 associated neurocognitive disorders, with the
ultimate goal of providing novel therapeutic targets for the treatment of this
condition.
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CHAPTER 2
HIV-1 TAT-INDUCED INHIBITION OF DOPAMINE TRANSPORT BY THE
HUMAN NOREPINEPHRINE TRANSPORTER IS ATTENUATED BY
TYROSINE-467 MUTATIONS1

1

Strauss, M., Quizon, P.M., Davis S.E., Yuan, Y., Martinez-Muniz, G., Porter, K.D.,
Zhan, C., & Zhu, J (2020). HIV-1 Tat-induced inhibition of dopamine transport by the
human norepinephrine transporter is attenuated by tyrosine-467 mutations. In
preparation for submission to The Journal of NeuroImmune Pharmacology.
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ABSTRACT: The HIV-1 Tat protein is capable of disrupting normal dopaminergic

transmission, which has been implicated as a central factor in the development of
HIV-1 associated neurocognitive disorders. We have previously demonstrated
that HIV-1 Tat inhibits dopamine (DA) re-uptake through the human DA
transporter (hDAT) by interacting with specific residues on hDAT, including
tyrosine470. Based on computational modeling and simulations, we predicted
that HIV-1 Tat may also inhibit the human norepinephrine (NE) transporter
(hNET) by interacting with a similar residue on hNET, tyrosine467. Thus, the
current study sought to examine the effects of mutating NET tyrosine467 to a
histidine (Y467H) or a phenylalanine (Y467F). Compared to wild type hNET (WT
hNET), Y467F displayed an 85% increase in the Km of [3H]NE uptake, while no
other changes were observed in the Vmax or Km of [3H]DA or [3H]NE uptake, or
surface expression of hNET. The Bmax or Kd of [3H]WIN 35,428 binding was not
altered in either mutant, although the Bmax of [3H]Nisoxetine binding for Y467H
was decreased by 30% compared to WT hNET, with no observed differences in
Kd. Additionally, the affinity of nisoxetine to inhibit [3H]DA uptake was increased
by 40% in Y467H compared to WT hNET, with no other alterations in inhibitory
activity for DA, nisoxetine, or cocaine observed for [3H]DA or [3H]NE uptake. Both
Y467H and Y467F were able to attenuate the Tat-induced inhibition in [3H]DA
uptake, providing mechanistic insight for the development of novel small
molecules which may attenuate the Tat/DAT and Tat/NET interaction.
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GRAPHICAL ABSTRACT

HIV-1 Tat inhibits dopamine uptake through human norepinephrine (hNET)
transporter on the presynaptic terminal via a direct allosteric interaction. hNET
Tyrosine 467 is predicted to have a cation-π interaction with HIV-1 Tat
Methionine 1. Mutating Tyrosine 467 to Histidine or Phenylalanine attenuates this
inhibitory effect by disrupting the Tat-hNET interaction.

2.1 INTRODUCTION
Despite the success of combinatorial antiretroviral therapy (cART) in
controlling peripheral HIV infection and improving the lives of HIV patients,
roughly 50% of the 38 million HIV-positive patients (HIV.gov) will develop
neurological complications including cognitive dysfunction, motor deficits, and
dementia collectively referred to as HIV-associated neurocognitive disorders
(HAND; Heaton et al., 2010). Most cART medications cannot cross the bloodbrain barrier, while infected macrophages carrying the virus can (Buckner et al.,
2006), allowing the CNS to serve as an HIV-viral reservoir (Brack-Werner, 1999;
Marban et al., 2016). The replication and expression of viral proteins in the CNS
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is associated with the persistence of HIV-related neuropathology and subsequent
neurocognitive deficits (Brack-Werner, 1999; Frankel and Young, 1998, Johnston
et al., 2001; Power et al., 1998) and is central to the development of HAND
(Gaskill et al., 2009). Specifically, the continuing presence of the transactivator of
transcription (Tat) protein in cART-treated HIV patients (Johnson et al., 2013)
may play a crucial role in the neurotoxicity and cognitive impairment evident in
HAND (King et al., 2006; Rappaport et al., 1999). Considering long-term viral
protein exposure can accelerate damage to the mesocorticolimbic dopamine
(DA) system (Nath et al., 1987; Berger and Arendt, 2000; Koutsilieri et al., 2002),
and HIV-1 Tat has been detected in DA-rich brain areas (Del Valle et al., 2000;
Hudson et al., 2000; Lamers et al., 2010), defining the molecular mechanism(s)
by which HIV-1 Tat impairs the DA system and affects the progression of HAND
may provide valuable insight into the development of novel therapies for this
population.
Converging lines of clinical observations, supported by imaging (Chang et
al., 2008; Wang et al., 2004), neuropsychological performance testing (Kumar et
al., 2011; Meade et al., 2011), and postmortem examinations (Gelman et al.,
2012), have demonstrated that DA dysregulation is correlated with the abnormal
neurocognitive function observed in HAND. Exposure to viral proteins may lead
to elevated DA and decreased DA turnover in the early stages of HIV-infection
(Scheller et al., 2010), while long-lasting exposure results in a dopamine
transporter (DAT) deficit that potentiates HAND severity and accelerates its
progress (Purohit et al., 2011; Chang et al., 2008; Wang et al., 2004). DA
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transporter (DAT)-mediated DA re-uptake is critical for maintaining normal DA
homeostasis, and our previously published work has demonstrated that
exogenous application of recombinant HIV-1 Tat1-86 protein decreases DAT
activity in cells (Midde et al., 2013; Midde et al., 2015; Quizon et al., 2016) and
rat brain synaptosomes (Zhu et al., 2009b) via a direct allosteric mechanism
(Yuan et al., 2015; Yuan et al., 2016).
In addition to the DAT, the norepinephrine transporter (NET) may also
participate in DA re-uptake in brain regions with relatively low levels of DAT
expression, particularly the prefrontal cortex (Moron et al., 2002; Masana et al.,
2011; Devoto & Flore, 2006), a brain area underlying many of the cognitive
capabilities frequently affected in HAND. Our previous work on the DAT has
utilized a computational modeling and experimental validation approach to
determine the key residues on the DAT which are involved in the Tat/DAT
interaction. For example, we determined that a single point mutation of DAT at
tyrosine470 (to a histidine, Y470H) alters basal DA uptake but attenuated the
inhibitory effects of HIV-1 Tat1-86 on DA transport (Midde et al., 2013).
Importantly, the NET displays identical residues to those which we have
identified as being critical to the Tat/DAT interaction (Yuan et al., 2016), one of
which is DAT-Tyr470, which aligns with NET-Tyr467. To the best of our
knowledge, the mechanism(s) of Tat interacting with NET has been heretofore
unexplored. In the present study, we mutated NET-Tyr467 to either a histidine
(Y470H) or a phenylalanine (Y470F) in order to determine the role of this residue
in basal DA transport and the Tat/NET interaction. Ultimately, identifying specific
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binding sites which are similar between Tat/DAT and Tat/NET and their
respective roles in the DA transport process may be beneficial to attenuating the
inhibitory effect of Tat on dopaminergic transmission by providing a molecular
basis for the development of novel compounds, which may serve as an early
intervention strategy in HIV-1 infection.
2.2 MATERIALS AND METHODS
2.2.1 Predicting the interaction site between hNET and HIV-1 Tat
The complex structure of hNET binding with HIV-1 Tat was constructed
based on our previous reported hDAT/Tat complex structure (Yuan et al., 2015)
via homology modelling. Sequence alignment among three major monoamine
transporters

was

performed

by

using

PROMALS3D

server

(http://prodata.swmed.edu/promals3d/; Pei et al., 2008) on the amino acid
sequences of the human norepinephrine transporter (NET, accession number as
P23975 in protein sequence database of UniProt (Yuan 2011), the human DAT
(hDAT, accession number of Q01959), and the human serotonin transporter
(SERT, accession number as P31645). The Modeller module of Discovery Studio
2.5 (Studio, D. 2009) was used to build the structure of hNET/Tat complex with
using the structure of hDAT/Tat complex as template. 1ns backbone-restrained
MD simulations were performed on the energy-minimized hNET/Tat complex at
the physiological environment.
2.2.2 Construction of Plasmids
The Tyr467 mutation was chosen based on predictions of computational
modeling and simulations (Figure 2.1) and our previous studies investigating a
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homologous residue (Tyr 470) on the dopamine transporter (Midde et al., 2013;
Midde et al., 2015; Yuan et al., 2016; Yuan et al., 2015). Mutation of Tyr467 to
Histidine (Y467H) or Phenylalanine (Y467F) is expected to abolish a critical
hydrogen bond between hNET and HIV-1 Tat. The 467H and 467F mutations
were generated based on the wild type hNET (WT hNET) sequence (NCBI,
cDNA clone MGC: 190603 IMAGE: 100062757) by site-directed mutagenesis.
Synthetic cDNA encoding hNET subcloned into pcDNA3.1+ was used as a
template to generate mutants using the QuikChange™ site-directed mutagenesis
Kit (Agilent Tech, Santa Clara CA). The sequences of the mutant constructs were
confirmed at the University of South Carolina EnGenCore facility. DNA plasmids
were propagated and purified using a Qiagen Plasmid Maxi Kit (Valencia, CA).
2.2.3 Cell culture and DNA transfection
Rat pheochromocytoma cells (PC12 cells, CRL-1721, American Type
Culture Collection (ATCC), Manassas, VA), which were maintained in Dulbecco’s
modified eagle medium (DMEM, Life Technologies, Carlsbad, CA) and
supplemented with 15% horse serum, 2.5% bovine calf serum, 2 mM glutamine
and antibiotics, 100 U/mL penicillin and 100 µg/mL streptomycin. Cells were
cultured at 37 °C in a 5% CO2 incubator. For the intact cell experiments, once
cells grew to 100% confluence on 10 cm plates they were seeded at a density of
1 × 105 cells/cm2 in 24-well plates and transfected with 0.8 g of WT hNET,
Y467H, or Y467F plasmid DNA per well using Lipofectamine 2000 (Life
Technologies) 24 hours after seeding. Intact cells seeded in 24-well plates were
used for experiments 24 hours following transfection. For cell suspension assays,
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100% confluent 10 cm plates were transfected with 24 g of WT hNET, Y467H,
or Y467F plasmid DNA using Lipofectamine 2000 (Life Technologies) and used
for experiments 24 hours later.
2.2.4 [3H]Dopamine and [3H]Norepinephrine uptake assays
The maximal velocity (Vmax) and Michaelis-Menton constant (Km) of
[3H]Dopamine ([3H]DA) or [3H]Norepinephrine ([3H]NE) uptake was evaluated in
PC12 cells transfected with WT, Y467H, or Y467F hNET using a procedure
modified from our previous reports (Sun et al., 2019; Sun et al., 2017; Midde et
al., 2013). 24 hours following transfection, intact cells in 24-well plates were
washed twice with Krebs-Ringer-HEPES (KRH) buffer (final concentration in mM:
125 NaCl, 5 KCl, 1.5 MgSO4, 1.25 CaCl2, 1.5 KH2PO4, 10 D-glucose, 25 HEPES,
0.1 EDTA, 0.1 pargyline, and 0.1 L-ascorbic acid; pH 7.4). Cells were then
preincubated for 10 min at room temperature in 450 μL of KRH buffer with or
without 10 μM nomifensine (for [3H]DA uptake) or 10 μM desipramine (for [3H]NE
uptake) to determine nonspecific binding. Following the 10 min incubation, cells
were incubated for an additional 8 min at room temperature in the presence of
one of six concentrations of unlabeled DA or NE (final concentrations 0.03-5 μM)
combined with a fixed concentration of [3H]DA (500,000 dpm/well, specific activity
40 Ci/mmol; PerkinElmer Life and Analytical Sciences, Boston MA) or [ 3H]NE
(500,000 dpm/well, specific activity 14.5 Ci/mmol; PerkinElmer Life and Analytical
Sciences, Boston MA), respectively. Specific hNET-mediated DA or NE uptake
was calculated by subtracting the non-specific uptake (in the presence of
nomifensine or desipramine) from the total uptake. The reaction was terminated
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by the removal of solution from the wells followed quickly by three washes with
ice-cold KRH buffer. Cells were then lysed in 500 μL of 1% SDS for one hour and
radioactivity was measured using a liquid scintillation counter (Tri-Carb 2900TR;
PerkinElmer Life and Analytical Sciences, Waltham, MA). To determine if the
Y467H or Y467F mutations alter the affinity of NET substrates or inhibitors, we
performed competitive inhibition of DA or NE uptake in intact PC12 cells
transfected as described above. Cells were preincubated with a series of final
concentrations of DA (1 nM – 1 mM), nisoxitine (0.1 nM – 100 μM), or cocaine (1
nM – 100 μM) at room temperature for 10 min followed by an additional 8 min
incubation with a fixed concentration of [3H]DA (50 nM, final concentration).
To assess whether the Y467H or Y467F mutations could attenuate the
inhibitory effects of HIV-1 Tat on hNET, we performed [3H]DA uptake in PC12
cells transfected with WT or mutant hNET in the presence or absence of HIV-1
Tat protein. Cells were dissociated with trypsin/EDTA (0.25%/0.1%, 1 mL for
each 10 cm dish), resuspended in culture medium, and incubated at room
temperature for 10 min. The dissociated cells were pelleted by centrifugation at
400 × g for 5 min at 4 °C and then washed once with phosphate-buffered saline
followed by additional 5 min centrifugation (400 × g, 4 °C). The resulting cell
pellets were then resuspended in KRH assay buffer. The cell suspensions from
WT, Y467H, or Y467F mutants were then preincubated with or without
recombinant Tat1–86 (rTat1–86, 140 nM, final concentration, ImmunoDx, Woburn
MA) at room temperature for 20 min followed by additional 8 min incubation with
mixed [3H]DA (50 nM, final concentration). Non-specific [3H]DA uptake was
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determined in the presence of 10 µM desipramine. The reaction was terminated
by immediate filtration through Whatman GF/B glass filters (presoaked for 2 h
with 1 mM pyrocatechol) followed by three washes with ice-cold KRH buffer
containing pyrocatechol using a Brandel cell harvester (model M-48; Brandel
Inc., Gaithersburg, MD). Radioactivity was determined as described above.
2.2.5 [3H]WIN 35,428 and [3H]Nisoxetine binding assays
Binding assays were used in order to determine the kinetic parameters
(Bmax and Kd) of [3H]WIN 35,428 and [binding in PC12 cells in suspension
transfected with WT, Y467H, or Y467F mutants (cell suspension preparation and
transfection as described above). Following cell suspension preparation, the cell
pellet was resuspended in 1 mL of binding buffer (15 mM Na2HPO4, 30 mM
NaH2PO4, 122 mM NaCl, 5 mM KCl, 1 mM MgSO4, 10 mM glucose, 1 mM
CaCl, and 10 nM EDTA; adapted from Zhen et al., 2012). 25 μL of cell
suspension was added to tubes containing 200 μL of assay buffer with or without
10 μM desipramine (for nonspecific binding) and preincubated for 5 min at 25 C.
Following preincubation, 25 μL of one of six concentrations of unlabeled -CFT
(final concentrations 1-30 nM) combined with a fixed concentration of [ 3H]WIN
35,428 (250,000 dpm/well, specific activity 82.9 Ci/mmol; PerkinElmer Life and
Analytical Sciences, Boston MA) was added to each tube (final volume 250 μL)
and incubated for an additional 15 min at 25 C. The reaction was terminated by
immediate filtration through Whatman GF/B glass filters (presoaked for 2 h with
1 mM pyrocatechol) followed by three washes with ice-cold assay buffer using a
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Brandel cell harvester (model M-48; Brandel Inc., Gaithersburg, MD) and
radioactivity was determined as described above.
The [3H]Nisoxetine binding assays were performed identically to the
[3H]WIN 35,428 binding assays with the following modifications: (1) The same
concentrations of unlabeled and [3H]Nisoxetine (250,000 dpm/well, specific
activity 82.0 Ci/mmol) were used instead of [3H]WIN 35,428, and (2) instead of
being resuspended in 1 mL assay buffer, for the [3H]Nisoxetine binding assays
the cells were counted after being suspended in 1 mL assay buffer, and then
diluted to a concentration of 100,000 cells/ 25 μL.
2.2.6 Cell Surface Biotinylation
To determine if the hNET mutations alter NET surface expression,
biotinylation assays were performed as described previously (Quizon et al.,
2016). PC12 cells were cultured on 6-well plates at a density of 105 cells/well. 24
hours after seeding in the 6-well plates, PC12 cells were transfected with WT,
Y467H, or Y467F hNET as described. Cells were incubated with 1 mL of
1.5 mg/mL of sulfo-NHS-SS biotin (Pierce, Rockford, IL) in PBS/Ca/Mg buffer
(138 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 9.6 mM Na2HPO4, 1 mM MgCl2,
and 100 nM CaCl2, pH 7.3). After incubation, cells were washed 3 times with
1 mL of ice-cold PBS/Ca/Mg buffer containing 100 mM glycine and incubated for
30 min at 4 °C in the same buffer. Cells were then washed 3 times with 1 mL of
ice-cold PBS/Ca/Mg buffer and then lysed by addition of 500 ml of Lysis buffer
(1% Triton X-100, 10 mM Tris HCl, 150 mM NaCl, 1 mM EDTA, and 250 μM
phenylmethylsulfonyl fluoride), followed by incubation and continuous shaking for
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20 min at 4 °C. Cells were transferred to 1.5 mL tubes and centrifuged at
20,000 × g for 20 min. The resulting pellets were discarded, and 100 μL of the
supernatants were stored at −20 °C for determination of total NET. Remaining
supernatants were incubated with continuous shaking in the presence of
monomeric avidin beads in Triton X-100 buffer (100 μL/tube) for 1 h at room
temperature. Samples were centrifuged subsequently at 17,000 × g for 4 min at
4 °C, and supernatants (containing the non-biotinylated, intracellular protein
fraction) were stored at −20 °C. Resulting pellets containing the avidin-absorbed
biotinylated proteins (cell-surface fraction) were resuspended in 1 mL of 1.0%
Triton X-100 buffer and centrifuged at 17,000 × g for 4 min at 4 °C, and pellets
were resuspended and centrifuged twice. Final pellets consisted of the
biotinylated proteins adsorbed to monomeric avidin beads. Biotinylated proteins
were eluted by incubating with 50 μl of Laemmli buffer for 20 min at room
temperature and stored at −20 °C for western blotting.
To obtain immunoreactive NET protein in total synaptosomal, intracellular,
and cell surface fractions, samples were thawed and subjected to gel
electrophoresis and western blotting. Samples were separated by 10% SDSpolyacrylamide gel electrophoresis for ~90 min at 125V. Samples were then
transferred to Immobilon-P transfer membranes (0.45 µm pore size; Millipore
Co., Bedford MA, USA) in transfer buffer (50 mM Tris, 250 mM glycine, 3.5 mM
SDS) using a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad; Hercules,
CA) for 90 min at 75 V. The membranes were then incubated with blocking buffer
(5% milk powder in PBS containing 0.5% Tween-20) for 1 h at room temperature,
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followed by incubation with mouse anti-NET (MAb tech, 17-1 monoclonal
antibody, diluted 1:1,000 in blocking buffer) overnight at 4 °C. Transfer
membranes were then washed three times with blocking buffer at room
temperature followed by incubation with anti-mouse-HRP (Cell Signaling, catalog
number 7076S diluted 1:5,000 in blocking buffer) for 1 h at room temperature.
Membranes were then washed an additional three times in PBS containing 0.5%
Tween-20 (Sigma-Aldrich; St. Louis, MO). Immunoreactive proteins on the
transfer membranes were detected using Amersham ECL prime western blotting
detection reagent (GE life sciences; Chicago, IL) and developed on Hyperfilm
(GE life sciences; Chicago, IL). After detection and quantification of NET each
blot was washed and re-probed with rabbit anti-Calnexin (Santa Cruz,
Biotechnology, catalog number SC-11397 polyclonal antibody, diluted 1:10,000
in blocking buffer), an endoplasmic reticular protein, to monitor protein loading
between all groups. Multiple autoradiographs were obtained using different
exposure times, and immunoreactive bands within the linear range of detection
were quantified by densitometric scanning using Scion image software. Band
density measurements, expressed as relative optical density, were used to
determine levels of NET in the total synaptosomal fraction, the intracellular
fraction (non-biotinylated), and the cell surface fraction (biotinylated).
2.2.7 Statistical Analysis
Results are presented as mean ± SEM, and n represents the number of
independent experiments for each experiment group. Kinetic parameters
(Vmax, Km, Bmax, and Kd) were determined from saturation curves by nonlinear
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regression analysis using a one-site model with variable slope. IC50 values for
substrate and inhibitors for [3H]DA or [3H]NE uptake were determined from
inhibition curves by nonlinear regression analysis using a one-site model with
variable slope. For experiments involving comparisons between unpaired
samples, unpaired Student’s t test was used to assess any difference in the
kinetic parameters (Vmax, Km, Bmax, Kd or IC50) between WT and hNET mutants;
log-transformed values of IC50, Km or Kd were used for the statistical
comparisons. Significant differences between samples were analyzed with
separate ANOVAs followed by post-hoc tests, as indicated in the results Section
of each experiment. All statistical analyses were performed using IBM SPSS
Statistics version 26, and differences were considered significant at p < 0.05.
2.3 RESULTS
2.3.1 Computational modeling: Tyr467 and functional relevant residues of human
NET
The computationally modeled NET-Tat binding mode is depicted in Figure
2.1. According to the modeled binding structure, the aromatic side chain of Y467
residue of NET has a favorable cation- interaction with the positively charged
amine group of M1 residue of Tat. Based on this computational insight, mutation
of Y467 to another residue with a non-aromatic side chain should considerably
weaken the favorable NET-Tat binding.
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(B)

(A)
NET-TAT

N-Y467
T-M1

Figure 2.1 Overview of hNET/TAT complex. (A) hNET and Tat are shown in
cyan and gold surface style, respectively. (B) Local view of cation- π interaction
between hNET-Y467 and TAT-M1 with labeled distance.
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2.3.2 Mutational effects of Tyr467 on hNET differentially influence DA or NE
uptake kinetics
To determine the functional influence of Tyr467 mutations on hNET
function, kinetic analysis of [3H]Dopamine ([3H]DA) or [3H]Norepinephrine
([3H]NE) uptake was performed in PC12 cells transfected with WT-, Y467A-, or
Y467F-hNET. As shown in Table 2.1, compared to WT hNET (Vmax: 57.0 ± 6.3
fmol/min/106 cells, Km: 0.219 ± 0.063 μM), neither Vmax or Km of [3H]DA uptake
was altered in Y467H (Vmax: 54.3 ± 6.7 fmol/min/106 cells, Km: 0.225 ± 0.049 μM)
and Y467F (Vmax: 59.3 ± 5.2 fmol/min/106 cells, Km: 0.129 ± 0.017 μM). For
[3H]NE uptake, no difference in Vmax was observed among WT hNET (52.6 ± 15
fmol/min/106), Y467H (74.4 ± 16 fmol/min/106), and Y467F (86.2 ± 30
fmol/min/106). Compared to WT hNET (0.179 ± 0.018 μM), Km was not
significantly altered in Y467H (0.596 ± 0.23 μM), but was increased in Y467F
(0.332 ± 0.026 μM, [t(6) = 4.7; p < 0.01, unpaired Student’s t test]).
To determine whether mutations of Tyr467 alter subcellular distribution of
NET, surface biotinylation followed by Western blot was performed. Three
subcellular fractions were prepared from PC12 cells transfected with WT, Y467H,
and Y467F hNET. NET immunoreactivity in both total, intracellular (nonbiotinylated), and the cell surface fraction (biotinylated) were examined (Figure
2.2). No differences between WT-, Y467H- or Y467F-hNET were found in the
ratio of total, nonbiotinylated or biotinylated NET to calnexin immunoreactivity,
indicating that mutations of Tyr467 do not alter NET surface expression.
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Table 2.1 Kinetic properties of the reuptake of [3H]DA and [3H]NE in PC12 cells
expressing WT hNET and its mutants

WT hNET

Y467H

Y467F

[3H]DA uptake
Vmax (fmol/min/106)

57.0 ± 6.3

54.3 ± 6.7

59.3 ± 5.2

Km (µM)

0.219 ± 0.063

0.225 ± 0.049

0.129 ± 0.017

[3H]NE uptake
Vmax (fmol/min/106)

52.6 ± 15

74.4 ± 156

86.2 ± 30

Km (µM)

0.179 ± 0.018

0.597 ± 0.23

0.332 ± 0.026*

*T=4.7, df = 6 p =0.0034
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Figure 2.2 Biotinylation and Western blotting to determine cell surface
expression of WT-, Y467F-, and Y467H-hNET. (A) Representative
immunoreactive blots for NET and calnexin (as control protein) in total, nonbiotinylated (intracellular) and biotinylated (surface expression) fractions. (B) NET
immunoreactivity for total, non-biotinylated and biotinylated expression is
expressed as mean ± S.E.M. densitometry units from 5 independent
experiments.
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2.3.3 Mutations of Tyr467 did not alter [3H]WIN 35,428 or [3H]Nisoxetine binding
to NET
Since both WIN35,428 and Nisoxetine label different locations on hNET
(Zhen et al., 2012), we examined the Bmax and Kd values of [3H]WIN 35,428 or
[3H]Nisoxetine to WT-, Y467H-, and Y467F-hNET. As shown in Table 2.2,
compared to WT hNET (Bmax: 0.267 ± 0.063 pmol/106 cells, Kd: 24.7 ± 3.1 nM),
the Bmax of [3H]WIN35,428 binding was not altered in Y467H (Bmax: 0.209 ± 0.034
pmol/106 cells) or Y467F (Bmax: 0.322 ± 0.078 pmol/106 cells). The Kd value was
not altered in Y467H (31.0 ± 3.1 nM), however it was increased in Y467F (34.2 ±
1.9 nM,[ t(6) = 2.5; p < 0.05, unpaired Student’s t test]).For [3H]Nisoxetine binding
(Table 2.2), compared to WT hNET (0.261 ± 0.023 pmol/106 cells), the Bmax value
was decreased in Y467H (0.183 ± 0.019 pmol/106 cells, [t(9) = 2.5; p < 0.05,
unpaired Student’s t test]) but not altered in Y467F (0.273 ± 0.031 pmol/106
cells). Additionally, no changes to the Kd value of [3H]Nisoxetine binding were
found between WT hNET (8.86 ± 1.0 nM) and Y467H (9.43 ± 1.3 nM) or Y467F
(9.62 ± 1.2 nM).
2.3.4 Mutational effects of Tyr467 on uptake inhibition potency of substrate and
inhibitors
We determined the ability of substrate (DA or NE) and NET inhibitors
(nisoxetine and cocaine) to inhibit [3H]DA or [3H]NE uptake in WT-, Y467H-, and
Y467F hNET to investigate whether Tyr467 mutations influence selective binding
sites on hNET (Table 2.3). For [3H]DA uptake, compared to WT hNET, the
apparent affinity (IC50) values for DA (1734 ± 20 nM) and cocaine (4377 ± 904

44

Table 2.2 Kinetic properties of [3H] WIN35,428 and [3H] Nisoxetine binding in
PC12 cells expressing WT hNET and its mutants

WT hNET

Y467H

Y467F

[3H]WIN 35,428
Bmax (pmol/106)

0.267 ± 0.063

0.209 ± 0.034

0.322 ± 0.078

Kd (nM)

24.7 ± 3.1

31.0 ± 3.1

34.2 ± 1.8

[3H]Nisoxetine
Bmax (pmol/106)

0.261 ± 0.023

0.183 ± 0.019*

0.27 ± 0.03

Kd (nM)

8.86 ± 1.0

9.44 ± 1.3

9.61 ± 1.2

*T=2.5, df = 9 p =0.0331
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Table 2.3 Inhibitory affinity of substrates and inhibitors for [3H]DA and [3H]NE
uptake in WT hNET and its mutants

WT hNET

Y467H

Y467F

IC50 for [3H]DA uptake (nM)
DA

174 ± 20

236 ± 21

125 ± 12

Nisoxetine

26.7 ± 4.0

15.9 ± 5.0*

21.1 ± 5.1

Cocaine

4377 ± 904

3920 ± 1010

4814 ± 964

IC50 for [3H]NE uptake (nM)
NE

775.6 ± 218

894.4 ± 258

802.4 ± 106

Nisoxetine

10.1 ± 2.3

9.69 ± 4.7

8.00 ± 3.4

Cocaine

6959 ± 2130

2258 ± 899

2888 ± 1320

*T=3.0, df = 4 p =0.0381
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nM) were not altered in Y467H (DA: 236 ± 21 nM, Cocaine: 3920 ± 1010 nM), or
Y467F (DA: 125 ± 12 nM, Cocaine: 4814 ± 964 nM). Compared to WT hNET
(26.7 ± 4.0 nM), the IC50 for nisoxetine inhibiting [3H]DA uptake was significantly
reduced in Y467H (15.9 ± 5.0 nM, [t(4) = 3.0; p < 0.05, unpaired Student’s t test])
but not altered in Y467F (21.1 ± 5.1 nM). For [ 3H]NE uptake, compared to WT
hNET, the IC50 values for NE (775 ± 218), nisoxetine (10.1 ± 2.3 nM), and
cocaine (6959 ± 2130 nM) were not altered in Y467H (NE: 894 ± 258 Nisoxetine:
9.69 ± 4.7 nM, Cocaine: 2258 ± 899 nM) or Y467F (NE: 802 ± 106, Nisoxetine:
8.00 ± 3.4 nM, Cocaine: 2888 ± 1320 nM).
2.3.5 Mutations of Tyr467 on hNET attenuate Tat-induced inhibition of DA
transport
We examined specific [3H]DA uptake in WT hNET and the Tyr467 mutants
in the presence or absence of 140 nM recombinant Tat 1-86. The inhibitory effects
of Tat1-86 on DA uptake via WT-, Y467H-, and Y467F-hNET are presented as the
ratio of [3H]DA uptake in the presence of Tat1-86 compared to [3H]DA uptake in
the absence of Tat for each respective mutant (Figure 2.3). One-way ANOVA
revealed a significant main effect of genotype. Post hoc analysis revealed 140
nM Tat1-86 produced a 35% decrease in the specific [ 3H]DA uptake in WT hNET
relative to its control [in DPM: Tat (2367 ± 426) vs control (3439 ± 443),[ t(16) =
2.5; p < 0.05, unpaired Student’s t test]; however, no effect of Tat on DA uptake
was observed in Y467H [in DPM: Tat (2291 ± 568) vs control (2321 ± 569)] or
Y467F [in DPM: Tat (2881 ± 145) vs control (3227 ± 458)], suggesting that
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Figure 2.3 Effects of Tat1-86 on the specific [3H]DA uptake in WT-, Y467H-, and
Y467F-hNET. PC12 cells transfected with the WT hNET or mutants were
preincubated with (white bars) or without (black bars) recombinant Tat1-86 (rTat186, 140 nM, final concentration) at room temperature for 20 min followed by the
addition of [3H]DA (50 nM, final concentration) for an additional 8 min at room
temperature. In parallel, nonspecific uptake was determined in the presence of
10 μM desipramine. Data are expressed as means ± S.E.M. from 4-9
independent experiments. * p < 0.05 compared to control value (in the absence
of Tat, unpaired Student’s t test).
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mutations of tyrosine 467 on hNET to a histidine or phenylalanine attenuate Tatinduced inhibition of DA uptake.
2.4 DISCUSSION
Our previous studies have demonstrated that DA uptake through the DAT
is inhibited by HIV-1 Tat through an allosteric interaction with specific residues on
the DAT. In addition to the DAT, the NET is also responsible for DA uptake in the
PFC, a critical brain region underlying cognitive capabilities frequently diminished
in HAND. For this reason, and because the NET displays identical residues to
the DAT at locations which we have demonstrated to be crucial for the Tat/DAT
interaction, the present study sought to determine if HIV-1 Tat interacts with a
similar group of residues on the NET. Computational modeling and simulations
predicted that the Tyr467 residue of the NET, which mimics Tyr470 on the DAT,
is crucial for HIV-1 Tat induced inhibition of DA transport. Consistent with this
prediction, our findings indicate that mutation of Tyr467 can attenuate the HIV-1
Tat induced inhibition of DA uptake observed in WT hNET. Our pharmacological
function assays suggest that mutation of Tyr467 may alter the affinity of both
substrates and inhibitors, as evidenced by changes in the Michaelis constant
(Km) of [3H]NE uptake and the maximal binding and inhibitory potency of
nisoxetine. Transmembrane 10 (TM10) of the NET, where Tyr467 is located,
makes up part of the secondary substrate binding site (S2), thus it is feasible that
the observed changes in affinity are due to conformational disruptions in this
pocket. Taken together, our results provide novel molecular insight into the HIV-1
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Tat/NET interaction and highlight the role of this residue in the substrate
transport process.
The long-range electrostatic attraction between the positively charged
HIV-1 Tat molecule and the negatively charged extracellular surface of NET
(Ravna et al., 2009) likely represents the driving force for the association of these
proteins. Our computational prediction of the binding mode is based on a series
of computational modeling studies including homology modeling, Brownian
(Gabdoulline and Wade, 1998) and molecular dynamics simulations. Considering
the fundamental question of how HIV-1 Tat interacts with the NET through
specific recognition binding sites to interrupt NET-mediated DA transmission, our
computational model predicted Tyr467 to have a favorable cation-π interaction
with HIV-1 Tat Met1. In support of the proposed model, our results demonstrate
that mutating Tyr467 alters the conformational state of the S2 binding site on
NET and, importantly, attenuates HIV-1 Tat induced inhibition of DA transport.
Additionally, these results provide evidence that our computationally simulated
model of the HIV-1 Tat/NET complex is a reliable method to predict the
intermolecular interactions between HIV-1 Tat and the NET, and support the idea
that the HIV-1 Tat/NET interaction involves similar residues as we previously
reported between HIV-1 Tat and the DAT (Midde et al., 2013; Midde et al., 2015).
Although mutation of Tyr467 was able to attenuate HIV-1 Tat-induced inhibition
of NET-mediated DA transport, our computational modeling and previous work
with the DAT suggest that multiple residues are likely involved in the HIV-1
Tat/NET interaction. With this in mind, determining the influence of additional
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single and multiple mutations to predicted recognition residues on the NET will
be an essential task for our future studies.
Tyr467 is located within a hydrophobic pocket of transmembrane helix 10
(TM10) of the NET where it makes up a portion of the S2 binding pocket (Wang
et al., 2012). The S2 binding pocket is functionally responsible for allosterically
triggering conformational changes from the occluded state to the inward-facing
state, facilitating the release of ions and substrate, and the residues located in
this pocket may take part in binding molecules before they reach the primary
substrate binding site (S1; Góral et al., 2020; Anderson et al., 2015). Because of
the critical role of both of these binding pockets in the uptake process they
represent common targets of NET inhibitors. Nisoxetine, a potent and selective
NET inhibitor, has been shown to induce inhibition through its interaction with the
S2 binding site (Manepalli et al., 2012; Anderson et al., 2015), whereas WIN
35,428, a cocaine analog, induces inhibition via interactions with the S1 binding
site (Manepalli et al., 2012; Ravna et al., 2006). Although these binding pockets
are located in close proximity, the binding of these two molecules to the NET has
been demonstrated to be mutually exclusive (Zhen et al., 2012). Our study
determined that mutation of Tyr467 to His (Y467H) or Phe (Y467F) did not have
a significant effect on the affinity of [3H]Nisoxetine or [3H]WIN 35,428 binding to
the transporter, although we did observe a decrease in the maximal binding
(Bmax) of [3H]Nisoxetine to the Y467H mutant. A previous report (Wang et al.,
2012) also found that mutation of Tyr467 reduced the Bmax of [3H]Nisoxetine and
suggested that it was due to a decrease in transporter expression. Regarding this
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possibility, we performed cell surface biotinylation for WT NET and the Tyr467
mutants to assess total and surface NET expression. Our results did not find any
significant difference in total or plasma membrane expression of the NET in
either mutant, suggesting that this decrease in binding was not due to a
decreased number of binding sites, although it is possible that this assays lacks
the necessary sensitivity to identify the relatively small decrease in Bmax (~30%).
Although [3H]nisoxetine and [3H]WIN 35,428 binding were unchanged in
the mutants, we did identify alterations in uptake kinetics and inhibitor activity.
We observed an ~85% increase in the Km of NE uptake in Y467F compared to
WT NET, indicating this mutant has a lower affinity for NE. This effect may be
due to the aforementioned role of TM10 in allosterically mediating conformational
transitions of the NET, as well as effects on the Y545-Y467-Y548 motif, which
may be involved in conformational conversions required for the transport of NE,
similar to the DA transport process of DAT (Yuan et al., 2016; Sun et al., 2019).
Despite the alterations in NE affinity, we did not identify any alterations in DA
uptake kinetics in these mutants, which may be due to the role of the S2 binding
pocket in controlling the entry pathway of substrates into S1 in the NET, where
mutations may differentially affect DA or NE interactions (Anderson et al., 2015).
We also found that the inhibition potency for nisoxetine to prevent [ 3H]DA uptake
was increased in Y467H, whereas the inhibition potencies of cocaine and DA
were unchanged. This is likely due to an altered conformation of the S2 binding
pocket (the target of nisoxetine), where Tyr467 is located, with the S1 binding
pocket (the target of cocaine and DA) being left intact. Collectively, the effects of
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the Tyr467 mutants on basal uptake kinetics and NET conformational integrity
are in agreeance with previous work and computational predictions suggesting a
role of this residue in the S2 binding pocket and nisoxetine binding.
Consistent with our computational modeling prediction, a vital finding in
the present study is that mutation of NET Tyr467 attenuates HIV-1 Tat induced
inhibition of NET reuptake functionality. Our modeling suggests that the Met1
residue of HIV-1 Tat forms a cation-π interaction with NET Tyr467. This
prediction is supported by our results demonstrating that mutation of Tyr467 to a
non-aromatic amino acid (His) attenuates this interaction. Interestingly, mutation
of Tyr 467 to an alternative aromatic amino acid (Phe) still produces attenuation
of the inhibitory effects of HIV-1 Tat. This result has several possible
explanations. One possibility is that, as noted above, mutation of Tyr467 may
induce conformational changes in the NET. These conformational changes may
alter the allosteric binding pocket on NET with which HIV-1 Tat interacts, thereby
attenuating its ability to inhibit reuptake. Additionally, as the driving force between
the Met-aromatic interaction is likely a combination of van der Waals,
electrostatic, and hydrophobic forces (Tatko & Waters, 2004; Rotello 1998), the
precise differences between the Met-Tyr and Met-Phe interactions will likely
require future investigation.
In conclusion, we provide novel evidence that inhibition of DA uptake by
HIV-1 Tat extends beyond the DAT and affects DA uptake via the NET as well.
Attenuation of HIV-1 Tat induced inhibition of NET reuptake via mutation of NET
Tyr467 supports our computational modeling prediction of the HIV-1 Tat/NET
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interaction and suggests that this interaction may be similar to our previously
reported HIV-1 Tat/DAT interaction. Future studies will aim to investigate the
contribution of multiple residues on NET which have been predicted to be
involved in the HIV-1 Tat/NET interaction, which may provide molecular insight
into the development of novel allosteric DAT/NET modulators that are capable of
attenuating the inhibitory effects of HIV-1 Tat on DA reuptake.
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CHAPTER 3
[3H]DOPAMINE UPTAKE THROUGH THE DOPAMINE AND
NOREPINEPHRINE TRANSPORTERS IS DECREASED IN THE
PREFRONTRAL CORTEX OF TRANSGENIC MICE EXPRESSING HIV-1 TAT
PROTEIN2

2

Strauss, Matthew, et al. "[3H] Dopamine Uptake through the Dopamine and
Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice
Expressing HIV-1 Transactivator of Transcription Protein." Journal of Pharmacology and
Experimental Therapeutics 374.2 (2020): 241-251.
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ABSTRACT: Dysregulation of dopamine neurotransmission has been linked to

the development of HIV-1 associated neurocognitive disorders (HAND). To
investigate the mechanisms underlying this phenomenon, this study utilized an
inducible HIV-1 transactivator of transcription (Tat) transgenic (iTat-tg) mouse
model,

which

demonstrates

brain-specific

Tat

expression

induced

by

administration of doxycycline. We found that induction of Tat expression in the
iTat-tg mice for either 7 or 14 days resulted in a decrease (~30%) in the Vmax of
[3H]DA uptake via both the dopamine transporter (DAT) and norepinephrine
transporter (NET) in the prefrontal cortex (PFC), which was comparable to the
magnitude (~35%) of the decrease in Bmax for [3H]WIN 35,428 and [3H]Nisoxetine
binding to DAT and NET, respectively. The decreased V max was not
accompanied by a reduction of total or plasma membrane expression of DAT and
NET. Consistent with the decreased Vmax for DAT and NET in the PFC, the
current study also found an increase in the tissue content of DA and
dihydroxyphenylacetic acid (DOPAC) in the PFC of iTat-tg mice following 7-day
administration of doxycycline. Electrophysiological recordings in layer V
pyramidal neurons of the prelimbic cortex from iTat-tg mice found a significant
reduction in action potential firing, which was not sensitive to selective inhibitors
for DAT and NET, respectively. These findings provide a molecular basis for
using the iTat-tg mouse model in the studies of NeuroHIV. Determining the
mechanistic basis underlying the interaction between Tat and DAT/NET may
reveal novel therapeutic possibilities for preventing the increase in comorbid
conditions as well as HAND.

56

3.1 INTRODUCTION
Acquisition of the Human Immunodeficiency Virus (HIV) leads to the
development of acquired immunodeficiency syndrome (AIDS) and continues to
be a global public health problem, with an estimated 37 million HIV-1 positive
individuals worldwide. Despite the success of combinatorial antiretroviral therapy
(cART) in controlling peripheral HIV infection and improving the life of HIV
patients, roughly 50% of HIV-1 patients develop a group of neurological
complications including cognitive dysfunction, motor deficits, and dementia
collectively referred to as HIV-associated neurocognitive disorders (HAND)
(Heaton et al., 2010). Persistent viral replication and expression of HIV-1 viral
proteins within the CNS are central to the development of HAND (Gaskill et al.,
2009), particularly since most cART medications cannot cross the blood-brain
barrier, while infected macrophages carrying the virus can (Buckner et al., 2006).
Considering long-term viral protein exposure can accelerate damage to the
mesocorticolimbic dopamine (DA) system (Nath et al., 1987; Berger and Arendt,
2000; Koutsilieri et al., 2002), there is a pressing need to define the molecular
mechanism(s) by which HIV-1 infection impairs the DA system and affects the
progression of HAND. HIV-1 viral proteins are associated with the persistence of
HIV-related neuropathology and subsequent neurocognitive deficits (Frankel and
Young, 1998; Power et al., 1998; Brack-Werner, 1999; Johnston et al., 2001).
Specifically, the continuing presence of the transactivator of transcription (Tat)
protein in CART-treated HIV patients (Johnson et al., 2013; Henderson et al.,
2019), may play a crucial role in the neurotoxicity and cognitive impairment
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evident in neuroAIDS (Rappaport et al., 1999; King et al., 2006), as the HIV-1 Tat
protein has been detected in DA-rich brain areas (Del Valle et al., 2000; Hudson
et al., 2000; Lamers et al., 2010) and in the sera (Westendorp et al., 1995; Xiao
et al., 2000) of HIV-1 infected patients (Johnson et al., 2013).
Maintaining a normal physiological DA system is essential for a variety of
brain activities involved in attention, learning, memory (Nieoullon, 2002; Cools,
2006), and motivation (Lammel et al., 2012; Tye et al., 2013). Converging lines of
clinical observations, supported by imaging (Wang et al., 2004; Chang et al.,
2008), neuropsychological performance testing (Kumar et al., 2011; Meade et al.,
2011), and postmortem examinations (Gelman et al., 2012), have demonstrated
that DA dysregulation is correlated with the abnormal neurocognitive function
observed in HAND (Berger and Arendt, 2000; Purohit et al., 2011). Therapynaïve HIV patients demonstrate increased levels of DA and decreased DA
turnover in the early stages of HIV infection (Scheller et al., 2010), which may
initiate compensatory mechanisms eventually resulting in decreased DA levels
(Sardar et al., 1996; Kumar et al., 2009; Kumar et al., 2011) and dopaminergic
neuron damage (Wang et al., 2004; Chang et al., 2008) in the advanced stages
of HIV infection.
DA transporter (DAT)-mediated DA reuptake is critical for maintaining
normal DA homeostasis. Human DAT (hDAT) activity is strikingly reduced in HIV1-infected patients, particularly those with a history of cocaine abuse, correlating
with the severity of HIV-1 associated cognitive deficits (Wang et al., 2004; Chang
et al., 2008). Our published in vitro work has demonstrated that exogenous
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application of recombinant Tat1-86 protein decreases DAT activity in cells (Midde
et al., 2013; Midde et al., 2015; Quizon et al., 2016) and rat brain synaptosomes
(Zhu et al., 2009b). This research raises a critical question of whether the in vitro
Tat-dysregulated DAT function can be replicated with in vivo biological
expression of Tat protein in an animal model, which may contribute to the
neurocognitive deficits observed in both these animals and HIV infected
individuals. Moreover, the prefrontal cortex is an important brain region for higher
cognitive function, where not only the DAT but also the norepinephrine (NE)
transporter (NET) is capable of DA reuptake (Moron et al., 2002). For this
reason, it is possible that Tat-induced dysfunction of DA system could be
mediated by inhibition of both DAT and NET. The inducible Tat transgenic (iTattg) mouse model recapitulates many aspects of the neuropathologies and
neurocognitive impairments observed in HAND (Kim et al., 2003) and represents
clinically relevant model of symptomatic NeuroHIV. Thus, investigating the
neuropathogenic role of DAT/NET-mediated dopaminergic transmission in the
brain of iTat-tg mice may provide mechanistic insight into the development of
cognitive deficits in HIV-1 infected population. This iTat-tg mouse model allows
for determination of how in vivo Tat protein expression influences dopaminergic
neurotransmission by inhibiting DAT and NET, which may contribute to the
development of HAND.
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3.2 MATERIALS AND METHODS
3.2.1 Animals
Male iTat-tg and G-tg mice breeding stock were provided by Dr. Jay P.
McLaughlin at the University of Florida College of Pharmacy (Gainesville, FL).
Mice in this colony were established from progenitors originally derived by Dr.
Johnny J. He (Kim et al., 2003), at the Rosalind Franklin University of Medicine
and Science (Chicago, IL). The iTat-tg mouse line genetically expresses a
“tetracycline-on (TETON)” system, which is integrated into the regulator for the
astrocyte-specific glial fibrillary acidic protein (GFAP) promoter and coupled to
the Tat1-86 coding gene, allowing astrocyte (brain)-specific Tat1-86 expression
induced by doxycycline (Dox) administration (Kim et al., 2003). The iTat-tg
mouse model facilitates the needed focus on Tat protein, allowing us to study
Tat-mediated dysregulation of DAT and NET. In contrast, the G-tg mice possess
the TETON system integrated into GFAP but lack the Tat 1-86 coding gene,
rendering them incapable of Tat expression, but highly suitable as control
subjects. Since the iTat-tg and G-tg mice are developed from C57BL/6J mouse
strain, C57BL/6J mice (obtained from the Jackson Laboratory, Bar Harbor, ME)
were used as another control mouse line. Mice used for all experiments were
between the age of 9-14 weeks (see Table A.4). This age range was chosen
based on the previous reports which found both physiological (Carey et al., 2013;
Cirino et al., 2020) and behavioral deficits (Carey et al., 2012; Paris et al., 2014;
Paris et al., 2015) in the iTat-tg mice using an identical age range. At the
completion of all experiments, we conducted the correlation analysis on the age
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with the respective experimental data values from individual animals following 7or 14-day administration of Dox, which revealed no correlation between age and
the respective experimental data values. Mice were housed (4-5 mice/cage) in a
temperature (21 ± 2 °C)- and humidity (50 ± 10%)-controlled vivarium, which
were maintained on a 12:12 h light/dark cycle (lights on at 07:00 h) with ad
libitum access to food and water. Animals were maintained in accordance with
the Guide for the Care and Use of Laboratory Animals under the National
Institute of Health (NIH) guidelines in the Assessment and Accreditation of
Laboratory Animal Care accredited facilities.

The experimental protocol was

approved by the Institutional Animal Care and Use Committee (IACUC) at the
University of South Carolina, Columbia.
3.2.2 Drug administration and Synaptosomal preparation
Male iTat-tg, G-tg, and C57BL/6J mice were administered either Dox (100
mg/kg/day, Sigma-Aldrich; St. Louis, MO) or saline (10 μl/gram body weight) via
intraperitoneal injection for 7 or 14 consecutive days. The optimized dose of Dox
was chosen because it has been previously proven efficacious for induction of
Tat (Zou et al., 2007; Carey et al., 2012; Paris et al., 2014b) and findings
showing that iTat so induced is biologically active during the period of behavioral
testing (Zou et al., 2007). The 7- or 14-Dox or saline treatment paradigm was
chosen for the kinetic analysis of DA uptake based on the previous behavior
studies (Carey et al., 2012; Carey et al., 2013; Paris et al., 2014a). In addition,
based on the previous report showing no significant difference in Tat
immunoreactivity in whole brain of iTat-tg mice following 7- or 14-day
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administration of Dox (Paris et al., 2014b), and because no difference in the
inhibitory effects of Tat on DA uptake were observed between these time points,
only 7-day administration paradigm was used in the subsequent studies.
Selection of animals for saline or Dox treatment was made randomly among
littermates.
All mice were rapidly decapitated 24 h after last saline or Dox injection.
Brain tissue dissected from prefrontal cortex (PFC, prelimbic and infralimbic
cortices combined), striatum, and hippocampus was pooled from a group of three
mice (constituting a single sample for each region), which was used as a single
replicate (n) for conducting independent experiments. Thus, “n” refers the
number of independent experiments conducted, rather than the number of mice
used. Synaptosomes were prepared using our published method (Zhu et al.,
2004). The PFC region was a focus of the current study because it is a critical
brain region for higher cognitive function (Miller and Cohen, 2001; Dalley et al.,
2004; Ridderinkhof et al., 2004), where the NET also plays a role in DA uptake
(Horn, 1973a; Raiteri et al., 1977). Given that DA uptake through DAT or NET is
not identical throughout various brain regions, the DA uptake through DAT in
striatum and NET in hippocampus were examined in addition to the PFC. The
striatum and hippocampus were also selected due to their central role in DA
neurotransmission (Horn, 1973b; Raiteri et al., 1977; Borgkvist et al., 2012). The
tissue was homogenized immediately in 20 mL of ice-cold 0.32 M sucrose buffer
containing 2.1 mM of NaH2PO4 and 7.3 mM of Na2HPO4, pH 7.4; with 16 up-anddown strokes using a Teflon pestle homogenizer (clearance approximately 0.003
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in.). Homogenates were centrifuged at 1,000g for 10 min at 4°C and the resulting
supernatants were then centrifuged at 12,000g for 20 min at 4°C. The resulting
pellets were resuspended in the respective buffer for each individual assay as
noted below.
3.2.3 Kinetic analysis of synaptosomal [3H]DA uptake assay
To determine whether Dox-induced biological Tat expression alters DA
uptake via DAT or NET, the maximal velocity (Vmax) and Michaelis-Menten
constant (Km) of synaptosomal [3H]DA uptake were examined using a previously
described method (Zhu et al., 2016). In a pilot

study, we measured the

synaptosomal [3H]DA uptake via DAT, NET, or the serotonin transporter (SERT)
in whole C57BL/6J mouse brain with the utilization of selective inhibitors for the
individual transporters and found that the portion of DA uptake via DAT, NET or
SERT is 80%, 17%, and 3%, respectively (data not shown). Due to the minimal
level of DA uptake via SERT, this transporter was not examined in the current
study. Importantly, although NET density is overall lower in the whole mouse
brain, in the PFC the NET is more concentrated than the DAT and plays a
primary role in reuptake of DA (Moll et al., 2000; Moron et al., 2002), and thus
warranted the present investigation. Because DA is transported by DAT, NET,
and SERT in the PFC (Moron et al., 2002; Williams and Steketee, 2004), kinetic
analysis of [3H]DA uptake via DAT in the PFC was assessed in the presence of
desipramine (1 uM) and paroxetine (5 nM) to prevent DA uptake into
norepinephrine- and serotonin-containing nerve terminals, respectively, whereas
[3H]DA uptake via NET in the PFC was assessed in the presence of GBR12909
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(100 nM) and fluoxetine (100 nM) to prevent DA uptake into dopaminergic- and
serotonin-containing nerve terminals, respectively. In brief, the resulting pellets
described above were resuspended in Krebs-Ringer-HPES assay buffer (125
mm NaCl, 5 mm KCl, 1.5 mm MgSO4, 1.25 mm CaCl2, 1.5 mm KH2PO4, 10 mm
glucose, 25 mm HEPES, 0.1 mm EDTA, 0.1 mm pargyline and 0.1 mm Lascorbic acid, saturated with 95% O2 ⁄ 5% CO2, pH 7.4). Aliquots of
synaptosomal tissue (50 μg/25 µL) were incubated with one of 6 mixed [ 3H]DA
concentrations containing a range of DA (Sigma-Aldrich; St. Louis, MO)
concentrations (1 nM - 5 µM) and fixed [3H]DA (12 nM, Perkin Elmer; Waltham,
MA) for 8 minutes at 37 °C. Incubation was terminated by the addition of 3 mL of
ice-cold assay buffer, followed by immediate filtration through Whatman GF/B
glass fiber filters (presoaked with 1 mM pyrocatechol for 3 h). Filters were
washed three times with 3 mL of ice-cold assay buffer using a Brandel cell
harvester

(Model

MP-43RS;

Biochemical

Research

and

Development

Laboratories Inc., Gaithersburg, MD). Radioactivity was determined by liquid
scintillation spectrometry (Model B1600TR, Packard Corporation Inc., Meriden,
CT). Bovine serum albumin (Sigma-Aldrich; St. Louis, MO) was used as a
standard (Bradford, 1976) to measure protein concentration for all samples.
Nonspecific uptake of [3H]DA into DAT or NET was determined in the presence
of 10 μM nomifensine (Sigma-Aldrich; St. Louis, MO) or 10 μM desipramine,
respectively.
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3.2.4 [3H]WIN 35,428 and [3H]Nisoxetine binding assays
[3H]WIN 35,428 and [3H]Nisoxetine (both purchased from Perkin Elmer;
Waltham, MA) represent substrate binding sites on the DAT and the NET,
respectively. To determine whether biological HIV-1 Tat expression alters these
substrate binding sites, we performed the saturation binding of [ 3H]WIN 35,428
and [3H]Nisoxetine for DAT and NET, respectively, using a previously described
method (Reith et al., 2005; Zhu et al., 2009a). Saturation binding assays were
conducted in duplicate in a final volume of 250 μL for PFC, striatum, and
hippocampus. For [3H]WIN 35,428 binding, 50 μL aliquots (50 μg protein) of
synaptosomes were incubated in 0.32M sucrose buffer (pH: 7.4) containing 2.1
mM NaH2PO4 and 7.3 mM Na2HPO4 (chemicals purchased from Sigma-Aldrich;
St. Louis, MO) with six concentrations of [3H]WIN 35,428 (1, 5, 10, 15, 25, 30 nM)
on ice for 2 h. Desipramine (1 µM) was included to inhibit [ 3H]WIN 35,428 binding
to the NET in the PFC. Nonspecific binding was determined in the presence of 10
µM cocaine in the striatum and 10 µM nomifensine in the PFC. For
[3H]Nisoxetine binding, 50 μL aliquots (50 μg protein) of synaptosomes were
incubated in assay buffer (150 mM Na2HPO4, 300 mM NaH2PO4, 1.22 M NaCl,
50 mM KCl, 12 mM MgSO4, 100 mM glucose, 10 mM CaCl, and 1 µM EDTA; pH:
7.4) with one of six Nisoxetine concentrations (0.5-30 nM) that was mixed with a
fixed concentration of [3H]Nisoxetine (3 nM) on ice for 2 h. 0.1 µM GBR 12909
was included to inhibit [3H]Nisoxetine binding to the DAT. Non-specific binding
was determined in the presence of 10 µM desipramine.

The reaction was

terminated by rapid filtration onto Whatman GF/B glass filter filters, presoaked for
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2 h with assay buffer containing 10% polyethylenimine, through a Brandel cell
harvester

(Model

MP-43RS;

Biochemical

Research

and

Development

Laboratories Inc., Gaithersburg, MD). Filters were washed three times with 3 mL
of ice-cold assay buffer. Radioactivity was determined by liquid scintillation
spectrometry (Model B1600TR, Packard Corporation Inc., Meriden, CT), and
bovine serum albumin (Sigma-Aldrich; St. Louis, MO) was used as a standard
(Bradford, 1976) to measure protein concentration for all samples.
3.2.5 Biotinylation and Western Blot Assay.
Biotinylation was performed to determine alterations in plasmalemmal
surface expression of DAT in the PFC and striatum and NET in the PFC and
hippocampus

following

Dox-induced

Tat

expression.

Following

7-day

administration of Dox or saline, synaptosomes were prepared as described
above. The biotinylation assay was performed as described previously (Zhu et
al., 2009a). Synaptosomes (800 µg/sample) prepared freshly were incubated in
500 µL of PBS Ca/Mg buffer (138 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, and
9.6 mM Na2HPO4; with 1 mM MgCl2 and 0.1 mM CaCl2; Sigma-Aldrich; St. Louis,
MO) containing 1.5 mg/mL EZ-link sulfo-NHS-biotin at 4 °C for 1 h. After
incubation, samples were centrifuged at 8000g for 4 min at 4 °C. To remove the
free sulfo-NHS-biotin, the resulting pellets were resuspended and centrifugated
three times with 1 mL of ice-cold 100 mM glycine in PBS/Ca/Mg buffer and
centrifugated at 8000g for 4 min at 4 °C.

Final resulting pellets were

resuspended in 1 mL of ice-cold 100 mM glycine in PBS/Ca/Mg buffer and
incubated with continual shaking for 30 min at 4 °C. Samples were centrifuged
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subsequently at 8000g for 4 min at 4°C, the resulting pellets were resuspended
in 1 ml of ice-cold PBS/ Ca/Mg buffer, and the resuspension and centrifugation
step were repeated twice. Final pellets were lysed by sonication for 2 to 4
seconds in 500 µL of Triton X-100 buffer (10 mM Tris, 150 mM NaCl, 1 mM
EDTA, 1.0% Triton X-100, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µM pepstatin,
250 µM phenylmethysulfonyl fluoride, pH 7.4), followed by incubation and
continual shaking for 20 min at 4°C. Lysates were centrifuged at 21,000g for 20
min at 4°C. Pellets were discarded, and 100 µL of supernatant was saved for
assessing total DAT or NET expression.

Monomeric avidin beads (100 µL,

Thermo Scientific; Waltham, MA) were added to the remaining supernatant and
incubated for one hour at room temperature. The samples were then centrifuged
at 17,000g for 4 min, and 100 µL of the resulting supernatant was saved for the
intracellular (non-biotinylated) fraction. Resulting pellets containing the avidinabsorbed biotinylation proteins (cell surface fraction) were resuspended in 1mL
of 1.0% Triton X-100 buffer and centrifuged at 17,000g for 4 min at 4°C, which
was repeated twice.

Final pellets containing the biotinylated DAT and NET

absorbed to monomeric avidin beads were eluted by addition of 50 µL of
laemmeli buffer (Sigma-Aldrich; St. Louis, MO) and incubated for 20 min at room
temperature. The total, intracellular and surface fractions were stored at -20 °C
until Western blot assay.
To obtain immunoreactive DAT and NET protein in total synaptosomal,
intracellular, and cell surface fractions, samples were thawed and subjected to
gel electrophoresis and western blotting. Samples were separated by 10% SDS-
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polyacrylamide gel electrophoresis for ~90 min at 125V. Samples were then
transferred to Immobilon-P transfer membranes (0.45 µm pore size; Millipore
Co., Bedford MA, USA) in transfer buffer (50 mM Tris, 250 mM glycine, 3.5 mM
SDS) using a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad; Hercules,
CA) for 90 min at 75 V. The membranes were then incubated with blocking buffer
(5% milk powder in PBS containing 0.5% Tween-20) for 1 h at room temperature,
followed by incubation with either goat anti-DAT (Santa Cruz, C-20 polyclonal
antibody, diluted 1:500 in blocking buffer) or mouse anti-NET (MAb tech, 05-1
monoclonal antibody, diluted 1:5,000 in blocking buffer) overnight at 4 °C.
Transfer membranes were then washed three times with blocking buffer at room
temperature followed by incubation with either anti-goat-HRP (Jackson
Laboratory, catalog number 305-035-045 diluted 1:10,000 in blocking buffer) or
anti-mouse-HRP (Cell Signaling, catalog number 7076S diluted 1:15,000 in
blocking buffer) for 1 h at room temperature. Membranes were then washed an
additional three times in PBS containing 0.5% Tween-20 (Sigma-Aldrich; St.
Louis, MO). Immunoreactive proteins on the transfer membranes were detected
using Amersham ECL prime western blotting detection reagent (GE life sciences;
Chicago, IL) and developed on Hyperfilm (GE life sciences; Chicago, IL). After
detection and quantification of DAT or NET each blot was washed and re-probed
with rabbit anti-Calnexin (Santa Cruz, Biotechnology, catalog number SC-11397
polyclonal antibody, diluted 1:10,000 in blocking buffer), an endoplasmic reticular
protein, to monitor protein loading between all groups. Multiple autoradiographs
were obtained using different exposure times, and immunoreactive bands within
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the linear range of detection were quantified by densitometric scanning using
Scion image software. Band density measurements, expressed as relative optical
density, were used to determine levels of DAT and NET in the total synaptosomal
fraction, the intracellular fraction (non-biotinylated), and the cell surface fraction
(biotinylated).
3.2.6 HPLC analysis of DA and dihydroxyphenylacetic acid (DOPAC) tissue
contents in brain regions
Concentrations of DA and DOPAC in PFC, nucleus accumbens, and
striatum in iTat-tg and G-mice following 7-day administration of saline or Dox
were determined using a high performance liquid chromatography (HPLC)
system coupled with electrochemical detection (HPLC–EC) as described
previously (Zhu et al., 2004). Twenty-four hours after the last injection of saline or
Dox, whole brains from individual mice were removed and immediately stored in
liquid nitrogen, and then stored at −80° C. To prepare samples for HPLC assay,
whole brains were sliced on top of an ice-cold plate and brain regions were
dissected by biopsy punches with a plunger system (Miltex). Brain tissues were
individually stored in 10 volume/tissue weight of 0.1 N perchloric acid at −80° C
until assay. Upon assay, samples were thawed on ice, sonicated and centrifuged
at 30,000 × g for 15 min at 4° C. For each sample, 20 µl of the resulting
supernatant was injected onto the HPLC system. Chromatograms were recorded
using EZ Chrom Elite software (Agilent, Santa Clara, CA). Retention times of DA
and DOPAC standards were used to identify respective peaks. Peak heights
were used to calculate the detected amounts of DA and DOPAC based on a
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standard curve generated from external standards. The HPLC–EC system
(Coulochem III, ThermoFisher Scientific, Columbia MD) consisted of a 582
solvent delivery system, an autosampler (Model 542), a reverse phase HPLC
column (MD-150, 3.2 x 150 mm, 3µm, product no 70-0636) and electrochemical
detector (cell 5014B). The mobile phase contained 124 mM citric acid
monohydrate, 50 mM Na2HPO4, 10 mM NaCl, 0.1 mM EDTA, 0.2% octylsulfonic
acid–sodium salt and 5% methanol (pH 3.0), using a flow rate of 0.5 ml/min.
Samples were kept at 4o C in a cooling tray in the autosampler.
3.2.7 Patch-clamp Electrophysiology
iTat and C57 mice were decapitated following isoflurane anesthesia 24 h
after the last Dox or saline injection. Brains were rapidly removed and coronal
slices (300 μm) containing the PFC were cut using a Vibratome (VT1000S; Leica
Microsystems) in an ice-cold artificial cerebrospinal fluid (aCSF, in mM: 130
NaCl, 3 KCl, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 1 MgCl2, and 2 CaCl2, pH
7.2–7.4, saturated with 95% O2 and 5% CO2) solution in which NaCl was
replaced with an equiosmolar concentration of sucrose. Slices were incubated in
aCSF at 32–34°C for 45 min and kept at 22–25°C thereafter, until transfer to the
recording chamber. All solutions had osmolarity between 305 and 315 mOsm.
Slices were viewed under an upright microscope (Eclipse FN1; Nikon
Instruments) with infrared differential interference contrast optics and a 40 ×
water-immersion objective. For recordings, the chamber was continuously
perfused at a rate of 1–2 mL/min with oxygenated aCSF heated to 32 ± 1°C
using an automated temperature controller (Warner Instruments). Recording
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pipettes were pulled from borosilicate glass capillaries (World Precision
Instruments) to a resistance of 4–7 MΩ when filled with the intracellular solution.
The intracellular solution contained the following (in mM): 145 potassium
gluconate, 2 MgCl2, 2.5 KCl, 2.5 NaCl, 0.1 BAPTA, 10 HEPES, 2 Mg-ATP, and
0.5 GTP-Tris, pH 7.2–7.3, with KOH, osmolarity 280–290 mOsm. Layer V
pyramidal neurons of the prelimbic cortex were identified by their morphology.
The layer V pyramidal neurons of the medial prefrontal cortex were selected for
two reasons: first, dopamine (D1) receptor expression is enriched in deeper
layers of the prefrontal cortex (Santana and Artigas, 2017), which are primarily
affected by HIV-1 Tat protein (Brailoiu et al., 2017; Kesby et al., 2017), second,
the neurons projects to subcortical nuclei have been suggested to play a critical
role in cognitive functioning (Douglas and Martin, 2004; Riga et al., 2014).
Current step protocols (from -500 to +500 pA; 20 pA increments; 500 ms step
duration) were run to determine action potential frequency versus current (f-I)
relationship. Drugs were applied via the Y-tube perfusion system modified for
optimal solution exchange in brain slices (Hevers and Luddens, 2002). Dopamine
(10 nM, final concentration) was initially applied alone, followed by the combined
application of dopamine (10 nM) and GBR-12909 (100 nM), followed by the
combined application of dopamine (10 nM), GBR-12909 (100 nM) and
desipramine (1 µM). All data were collected after a minimum of 2 min of drug
exposure. Currents were low-pass filtered at 2 kHz and digitized at 20 kHz using
a Digidata 1440A acquisition board (Molecular Devices) and pClamp10 software
(Molecular Devices). Access resistance (10–30 MΩ) was monitored during
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recordings by injection of 10 mV hyperpolarizing pulses. All analyses were
completed using Clampfit 10 (Molecular Devices).
3.2.8 Data analysis
Data are expressed as mean ± S.E.M., and n refers to the number of
individual experiments for each group. To analyze the kinetic parameters
(Vmax/Km and Bmax/Kd) of [3H]DA uptake or [3H]WIN 35,428 and [3H]Nisoxetine
binding, best fit non-linear regression analysis using a single site model was
conducted for each individual experiment using GraphPad Prism 8 software. To
determine whether a relationship existed between individual mouse age and the
respective experimental data, separate Pearson correlation analysis was
conducted. The kinetic parameters were then compared between the saline and
Dox treated groups for C57BL/6J or G-tg mice (to rule out any non-specific
effects of Dox administration) and subsequently for the iTat-tg mice using
unpaired Student’s t tests, which were conducted using IBM SPSS statistics
version 25. Analyses resulting in p < 0.05 were considered significant.
3.3 RESULTS
3.3.1 Expression of HIV-1 Tat produces a decrease in synaptosomal [3H]DA
uptake through both DAT and NET in the PFC.
To determine the effects of Dox-induced Tat expression on DA uptake via
DAT or NET, kinetic analyses of synaptosomal [3H]DA uptake were performed in
iTat-tg mice following 7- or 14-days of Dox administration. After 7-day
administration of Dox or saline (Figure 3.1A and B), the Vmax of [3H]DA uptake via
DAT and NET in the PFC was significantly reduced by 27 ± 4.8% [t(7.953) = 3.981,
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Figure 3.1 Kinetic analysis of synaptosomal [3H]DA uptake was determined in
the PFC of iTat-tg mice following 7- or 14-day administration of saline or Dox.
Synaptosomes were incubated with a range of mixed DA concentrations (0.1 – 5
µM, final concentration) containing a fixed concentration (12 nM) of [ 3H]DA. The
Vmax and Km values for [3H]DA uptake via DAT (A and C) or NET (B and D) in the
PFC of iTat-tg (iTat) mice following 7- (A and B) or 14- (C and D) day
administration of saline or Dox were calculated using non-linear regression
analysis with a one-site binding parameter and represent the means from five to
seven independent experiments ± S.E.M. * p < 0.05, ** p < 0.01 compared to
saline control group.
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p < 0.01] and 27 ± 6.8% [t(11) = 3.752, p < 0.01], respectively, compared to the
respective saline controls (Figure 3.1A and B). No changes in the Km values of
[3H]DA uptake via DAT were observed (Figure 3.1A), however the Km values of
[3H]DA uptake via NET of iTat Dox-treated mice were significantly reduced by 58
± 6.6% compared to saline-treated controls [t(11) = 3.708, p < 0.01] (Figure 3.1B).
After 14-day administration of Dox or saline, the Vmax values of [3H]DA uptake via
DAT (Figure 3.1C) and NET (Figure 3.1D) in the PFC were significantly
decreased by 30 ± 5.9% [t(9) = 2.356, p < 0.05] and 32 ± 3.1% [t(8) = 2.952, p <
0.05], respectively compared to saline-treated controls. No significant differences
in the Km of [3H]DA uptake via either DAT or NET were found (Figures 3.1C and
D). We also determined the Vmax and Km values of [3H]DA uptake in the striatum
and hippocampus where DAT and NET are dominantly expressed. Results
showed no observable difference in the Vmax and Km values of [3H]DA uptake via
DAT in the striatum and NET in hippocampus between saline- and Dox-treated
iTat-tg mice following either 7- or 14-day administration of Dox (Table 3.1). In the
current study, in addition to iTat-tg mice treated with saline as a control for Dox
treatment, C57BL/6J and G-tg mice were used as negative controls. No
differences in the Vmax and Km values of [3H]DA uptake via DAT and NET in those
brain regions were observed between saline- or Dox-treated mice (Tables A.1-3).
3.3.2 Expression of HIV-1 Tat does not alter plasmalemmal membrane
expression of DAT or NET in the PFC.
To determine whether the Tat expression-induced decrease in the Vmax of
[3H]DA uptake via DAT or NET in PFC was associated with an alteration of the
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Table 3.1 Kinetic properties of [3H]DA uptake and [3H]WIN 35,428 binding
or [3H]Nisoxetine binding in iTat-tg mice

Treatment duration

Striatum (DAT)

iTat-tg
Saline
7d
iTat-tg
Dox
iTat-tg
Saline
14d
iTat-tg
Dox

Hippocampus (NET)

Vmax
(pmol/min/mg)

Km (nM)

Vmax
(pmol/min/mg)

Km (nM)

15.6 ± 1.4

97.3 ± 6.6

0.898 ± 0.12

102 ± 23

15.6 ± 1.6

91.1 ± 3.4

0.926 ± 0.077

75.4 ± 14

67.6 ± 8.5

140 ± 11

1.96 ± 0.19

122 ± 18

68.4 ± 8.9

141 ± 10

1.86 ± 0.26

115 ± 24

Bmax
pmol/mg

Kd (nM)

Bmax
pmol/mg

Kd (nM)

iTat-tg
22.9 ± 3.7
20.3 ± 5.3
0.611 ± 0.10
13.4 ± 3.3
Saline
7d
iTat-tg
25.4 ± 5.4
18.3 ± 1.8 0.552 ± 0.096 15.4 ± 2.0
Dox
Data are expressed as mean ± S.E.M. values from five to seven independent
experiments performed in duplicate. 7d indicates 7-days of treatment and 14d
indicates 14-days.
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subcellular distribution of the transporters, biotinylation and immunoblot assays
were performed to assess cell surface and intracellular transporter localization.
Three subcellular fractions were prepared from the PFC, striatum, and
hippocampus of iTat-tg mice following 7-day Dox or saline administration and
DAT or NET immunoreactivity in both total fraction and cell surface fraction
(biotinylated) were examined. No differences in DAT or NET immunoreactivity in
PFC between saline- and Dox-treated iTat-tg mice were found in the ratio of total
or surface transporters to calnexin (Figure 3.2), indicating that the observed
decrease in the Vmax for DAT or NET is not due to alteration of the available
transporters on the cell surface. Moreover, no differences in the respective
immunoreactivity of DAT in striatum or NET in hippocampus between saline- and
Dox-treated iTat-tg mice were found in the ratio of total or surface transporters to
calnexin (Figure A.1). Additionally, no differences were observed in DAT or NET
immunoreactivity in the PFC, striatum, or hippocampus between saline- and Doxtreated control mice in the ratio of total or surface transporters to calnexin (Figure
A.2).
3.3.3 Expression of HIV-1 Tat produces a decrease in [3H]WIN 35,428 and
[3H]Nisoxetine binding in the PFC
[3H]WIN 35,428 and [3H]Nisoxetine are highly selective and potent
reuptake inhibitors with high affinity for the DAT and NET, respectively (TejaniButt, 1992; Pristupa et al., 1994). To determine whether Tat-induced decreases
in the Vmax of [3H]DA uptake via DAT or NET alter the respective substrate
binding sites, kinetic analyses of [3H]WIN 35,428 and [3H]Nisoxetine binding were
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Figure 3.2 Analysis of plasmalemmal surface expression of DAT and NET was
determined in the PFC of iTat-tg mice following 7-day administration of saline or
Dox. Synaptosomes were incubated with sulfo-NHS-biotin and Pierce monomeric
avidin beads and washed multiple times to isolate the DAT or NET, which was
present on the plasmalemmal membrane. Top panels: representative
immunoblots of total and biotinylated (Biotin) fraction of DAT (A) or NET (B) from
the PFC of iTat-tg (iTat) mice from Dox-treated and saline (SAL) control groups.
Calnexin was used as control protein. Bottom panels: the ratio of total or
biotinylated DAT (A) or NET (B) immunoreactivity to calnexin immunoreactivity
expressed as mean ± S.E.M. from five independent experiments.
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performed in the brain regions of iTat-tg mice following 7-day Dox or saline
administration. For [3H]WIN 35,428 binding sites, in comparison to saline
controls, the Bmax values in PFC of Dox-treated iTat-tg mice were decreased by
28 ± 2.7% [t(7) = 4.396, p < 0.01] (Figure 3.3A), with no change in Kd values.
However, no difference was observed in the Bmax values in striatum between
saline-and Dox-treated iTat-tg mice (Table 3.1). For [3H]Nisoxetine binding sites,
the Bmax values in the PFC of Dox-treated iTat-tg mice was reduced by 36 ± 7.7%
compared to saline-treated controls [t(7) = 2.479, p < 0.05] (Figure 3.3B). The Kd
value was reduced by 40 ± 10% compared to saline-treated controls [t(8) = 2.670,
p < 0.05] (Figure 3.3B). No difference in the Bmax values in hippocampus were
found between saline-and Dox-treated iTat-tg mice (Table 3.1). Moreover, no
differences were observed between saline- or Dox-treated control mice (Tables
A.1 and A.2).
Due to the comparable decreases observed in the Vmax of [3H]DA uptake
and the Bmax of [3H]WIN 35,428 binding for the DAT in the PFC of Dox-treated
iTat mice, comparison of the turnover rate (Vmax/Bmax) revealed no significant
differences between saline (2.43 ± 0.14) and Dox (2.16 ± 0.29) treated groups
(Figure 3.3C). Analysis of the ratio of Km and Kd for Vmax of [3H]DA uptake and
the Bmax of [3H]WIN 35,428 binding for the DAT in the PFC also revealed no
significant differences between saline (0.014 ± 0.005) and Dox (0.009 ± 0.001)
treated mice (Figure 3.3D). No significant differences were found in turnover rate
for [3H]DA uptake and [3H]Nisoxetine binding for the NET in the PFC between
saline (3.40 ± 0.38) and Dox (3.66 ± 0.19) treated mice (Figure 3.3E), or for the
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PFC [3H]WIN 35,428
Bmax
Kd
iTat - SAL 0.445 ± 0.020 9.70 ± 0.24
iTat - DOX 0.321 ± 0.019** 9.89 ± 1.8
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Figure 3.3 Saturation binding of [3H]WIN 35,428 or [3H]Nisoxetine in the PFC of
iTat-tg mice following 7- day administration of saline or Dox. For [3H]WIN 35,428
binding to DAT, synaptosomes were incubated in assay buffer with one of six
concentrations of [3H]WIN 35,428 (1-30 nM, final concentration) and 1 µM
desipramine on ice for 2 h. Nonspecific binding was determined in the presence
of 10 µM cocaine. For [3H]Nisoxetine binding to NET, synaptosomes were
incubated in assay buffer with one of six concentrations of nisoxetine (0.5-30 nM,
final concentration) along with a fixed concentration of [ 3H]Nisoxetine (3 nM) and
0.1 µM GBR12909 on ice for 2 h. Nonspecific binding was determined in the
presence of 10 µM desipramine. The Bmax and Kd values for [3H]WIN 35,428 (A)
or [3H]Nisoxetine (B) binding to DAT or NET in the PFC of iTat-tg (iTat) mice
following 7- day administration of saline or Dox were calculated using non-linear
regression analysis with a one-site binding parameter and represent the means ±
S.E.M. from five independent experiments. * p < 0.05, ** p < 0.01 compared to
saline control group. DA turnover rate values were determined for DAT from (C)
the Vmax of [3H]DA uptake (Figure 3.1A)/Bmax of [3H]WIN 35,428 binding and (D)
the Km/Kd of [3H]DA uptake (Figure 3.1A)/Bmax of [3H]WIN 35,428 binding and for
NET from (E) the Vmax of [3H]DA uptake (Figure 3.1B)/Bmax of [3H]Nisoxetine
binding and (F) the Km/Kd of [3H]DA uptake (Figure 3.1B)/Bmax of [3H]Nisoxetine
binding.
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ratio Km and Kd in the saline (0.013 ± 0.003) and Dox (0.011 ± 0.001) treated
groups (Figure 3.3F).
3.3.4 The decreased DAT and NET function in the PFC is consistent with
alterations in DA and DOPAC tissue content
Given the critical role of the DAT and the NET in controlling DA
homeostasis, a Tat-induced decrease in DA reuptake via DAT or NET in the PFC
could result in alterations in the levels of DA and its primary metabolite DOPAC
in the respective brain regions. DA and DOPAC content were determined in PFC
and striatum from iTat-tg and G-tg mice following 7-day administration of saline
or Dox. As shown in Figure 3.4, DA tissue content in PFC from Dox-treated iTattg mice was increased by 268% (0.078 ± 0.021 ng/mg tissue) compared to saline
(0.021 ± 0.011 ng/mg tissue) treated controls [t(8) = 2.39, p < 0.05] (Figure 3.4A).
Similarly, DOPAC tissue content in the PFC of Dox-treated iTat-tg mice was
increased by 144% (0.036 ± 0.006 ng/mg tissue) compared to saline (0.015 ±
0.003 ng/mg tissue) treated controls [t(7) = 3.344, p < 0.05] (Figure 3.4B).
However, neither DA or DOPAC content in striatum of iTat-tg mice differed
significantly between saline- and Dox-treated groups (Figure 3.4C and D). We
also examined the tissue levels of DA and DOPAC content in the PFC and
striatum of G-tg mice, which showed no significant differences between salineand Dox-treated groups (Figure A.3).
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Figure 3.4 DA and dihydroxyphenylacetic acid (DOPAC) tissue content in the
PFC and striatum of iTat-tg mice following 7-day administration of saline or Dox.
Top panels: DA (A) and DOPAC (B) tissue content in the PFC of iTat-tg (iTat)
mice from Dox-treated or saline (SAL) control groups. Bottom panels: DA (C)
and DOPAC (D) tissue content in striatum (STR) of iTat-tg mice from Dox-treated
or saline control groups. Data are expressed as ng/mg tissue (mean ± S.E.M.)
from 5-6 mice per group. * p < 0.05, compared to saline control group.
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3.3.5 Action potential frequency is decreased in layer V pyramidal neurons of the
prelimbic cortex of iTat-tg mice
To determine whether the Tat-induced decrease in DA uptake via
DAT/NET in the PFC alters electrical firing signaling of neurons in this region, we
performed whole-cell patch clamp electrophysiology on layer V pyramidal
neurons in the prelimbic region of PFC from iTat-tg mice following 7-day saline or
Dox treatment. As shown in Figure 3.5B, ANOVA analysis revealed a significant
main effect of current injection [F(10,

210)

= 82.52, p < 0.0001], and a significant

main effect of drug treatment (saline vs dox) [F(1, 21) = 5.77, p = 0.025], as well as
significant current × drug treatment interaction [F(10, 210) = 2.49, p = 0.008]. Doxtreated iTat-tg mice displayed a reduction of action potential output in this subset
of neurons, compared to saline control group (Bonferroni p < 0.05).

No

differences were observed between saline and Dox treated C57BL/6J mice
(Figure A.4).
Additionally, to assess the effects of inhibition of DAT or NET in the
prelimbic region of PFC by selective inhibitors for the respective transporter on
the observed decrease in action potential output, the basal action potentials from
pyramidal neurons of iTat-tg mice with Dox or saline treatment were
subsequently examined in the presence of DA (10 nM), DA + GBR-12909 (a
potent DAT inhibitor; 100 nM), and DA + GBR-12909 + desipramine (DMI; a
potent NET inhibitor, 1 µM). A two-way ANOVA with repeated measurement on
action potential in iTat-tg mice treated with saline (Figure 3.5C) and Dox (Figure
3.5D) revealed a significant main effect of current injection [saline: F(10,
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Figure 3.5 Whole-cell patch clamp electrophysiology was performed in layer V
pyramidal neurons of the prelimbic region of PFC in iTat-tg mice following 7-day
administration of saline or Dox. Coronal slices (300 µm) containing the prelimbic
cortex were cut with a Vibratome and incubated in an ice-cold artificial CSF
(aCSF) solution at 32–34°C for 45 min and kept at 22–25°C thereafter, until
transfer to the recording chamber. (A) Representative traces from iTat-tg mice
treated with saline (iTat-Saline) and Dox (iTat-Dox) following hyperpolarizing (200 pA) and depolarizing (+200 pA) current steps. Summary of basal action
potential frequency (B) and action potential frequency in response to acute
application of DA (10 nM) or DA + GBR 12909 (100 nM) or DA + GBR 12909 +
DMI (1 µM) of neurons from iTat-tg mice treated with saline (C) or Dox (D). * p <
0.05, n=15 and n=8 for saline and Dox treated mice, respectively.
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21.17, p <0.0001; Dox: F(10, 40) = 145.4, p <0.0001]; however, neither saline- or
Dox-treated mice displayed a significant main effect of drug exposure [saline: F (3,
24)

= 1.005, p =0.4; Dox: F(3, 12) = 1.945, p = 0.18]. Although the current injection ×

drug exposure interaction was not significant in saline-treated mice [F(30,

240)

=

0.788, p = 0.78], Dox-treated mice displayed a significant interaction between
current injection × drug exposure [F(30, 120) = 1.571, p = 0.05].
3.4 DISCUSSION
The current study investigated the mechanism by which inducible Tat
expression influences dopaminergic transmission in the PFC of iTat-tg mice. We
have demonstrated that in vitro HIV-1 recombinant Tat1-86 protein reduces [3H]DA
uptake though DAT in cells (Midde et al., 2013; Midde et al., 2015; Quizon et al.,
2016; Sun et al., 2017) and rat striatal synaptosomes (Zhu et al., 2009b). Our
current results show that the Vmax of [3H]DA uptake through both DAT and NET
was decreased in the PFC of iTat-tg mice following 7- or 14-day Dox-induced
Tat1-86 expression. We also observed corresponding decreases in the Bmax of
[3H]WIN35,428 and [3H]Nisoxitine binding in this region, suggesting that the
inhibitory effects of in vitro Tat on DAT and NET function can be replicated in the
PFC of the iTat-tg mouse model with in vivo biological Tat expression. Moreover,
we also observed increased DA and DOPAC tissue content in the iTat-tg mice,
which was again selective to the PFC, suggesting a neuroadaptive change in the
DA system, perhaps in compensation for iTat protein-induced inhibition of DAT
and NET function.
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The most intriguing observation is that the Vmax for DA uptake via DAT or
NET in the PFC was decreased (~30%) in iTat-tg mice following 7- or 14-day
administration of Dox, whereas no differences in Vmax were observed in the
striatum or hippocampus of the iTat-tg mice between saline- and Dox-treated
subjects. In addition, no differences in Vmax were found in these brain regions
between saline- and Dox-treated subjects in the control G-tg and C57BL/6J
mouse lines. These findings suggest that the Dox-induced Tat reduces DA
transport in the PFC by inhibiting both DAT and NET in a region-specific manner.
Moreover, following 7-day Dox treatment, the Bmax value for [3H]WIN 35,428
labeled DAT binding sites in the PFC was decreased by 28% in iTat-tg mice,
which is comparable to the magnitude of the decrease in Vmax for DAT, whereas
the Bmax value for [3H]Nisoxetine labeled NET binding sites in the PFC was
decreased by 35%, which was slightly more than the observed decrease in the
Vmax for NET. Interestingly, DA uptake turnover (Vmax/Bmax), the efficacy of DA
molecules being transported per second per uptake site (Lin et al., 2000), was
not altered in the PFC of iTat-tg mice, which is consistent with our previous
results showing no change in DA uptake turnover following in vitro exposure of
rat synaptosomes to Tat (Midde et al., 2012). The efficacy of DA uptake largely
depends on DAT expression in the plasma membrane, which is dynamically
modulated by a trafficking mechanism (Zhu and Reith, 2008). Results from the
surface biotinylation assay did not find any difference in total and plasma
membrane expression of DAT or NET in the PFC in iTat-tg mice between Doxand saline-treated groups, suggesting that the reductions in Vmax and Bmax are
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not due to Tat-induced transporter protein degradation or surface transporter
trafficking. We have demonstrated that DA transport to cytoplasmic pool via DAT
is a dynamic conversion of the transporter‘s conformation between the three
states (outward-open, outward-occluded, and inward-open) (Yuan et al., 2016)
and that the Tat protein allosterically regulates DAT activity by binding to DAT in
the outward-open state (Yuan et al., 2015; Zhu et al., 2018). Considering that
DAT and NET share similar binding residues for Tat based on computational and
homology modeling (Yuan et al., 2016), the Dox-induced Tat expression could
reduce both Vmax and Bmax for DAT/NET by interfering with the Tat-DAT/NET
binding sites and inducing a conformational change of DAT/NET from the
outward-open state to the outward-occluded state.
The equivariant expression of inducible Tat protein across all brain regions
in the iTat-tg mice subjected to 7 days of 100 mg/kg/day Dox treatment has been
confirmed by detecting Tat mRNA (Kim et al., 2003) and Tat immunoblotting
(Carey et al., 2012). A caveat, however, it is unclear what is the actual
concentration of Dox-induced Tat expression is at or around the synaptic
terminals, and how this effective concentration of Tat might be reflected in the
brain of HIV-infected patients remains unclear, as most studies investigating the
inhibitory effects of Tat on monoamine transporters are performed in vitro using
recombinant Tat. For example, exposure to 140 nM recombinant Tat 1-86 induces
about 30% reduction of DA uptake in cells expressing wild-type hDAT (Midde et
al., 2013; Midde et al., 2015; Quizon et al., 2016; Sun et al., 2017) and brain
synaptosomes (Zhu et al., 2009b). One study reported that a detectable Tat
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concentration in frontal cortical brain samples from HIV-1-infected patients is
about 140 pmol (Hudson et al., 2000), which is 1000-fold lower than in vitro
recombinant Tat used in reported studies. The Dox treatment of 100 mg/kg used
in this study has been shown to induce ~ 1 ng/mL Tat concentration in the iTat-tg
mouse brain (Kim et al., 2003), which is comparable to Tat protein levels
detected in sera of HIV+ patients (Westendorp et al., 1995; Xiao et al., 2000).
Nevertheless, our studies with in vitro and in vivo Tat exposure provide molecular
insight

into

the

mechanisms

underlying

Tat-induced

dysregulation

of

dopaminergic transmission via DAT and NET.
Consistent with the decreased Vmax for DAT and NET in PFC, the current
study found an increase in the tissue content of DA and DOPAC in the PFC of
iTat-tg mice 24 h after 7-day administration of Dox. Similar studies have
demonstrated increased DA content in the caudate putamen of iTat-tg mice 3
days after completing a 7-day Dox regiment (Kesby et al., 2016a), but decreased
ratios of DOPAC/DA in the same region 10 days after completing a 7-day Dox
regiment without changes in this ratio in PFC (Kesby et al., 2016b). Regarding
these results, effects of Tat on DA tissue content in specific brain regions may be
influenced by different Dox regiments and the timing of brain collection after Dox
treatment. Levels of extracellular DA in the synaptic cleft are controlled by
reuptake via plasma membrane transporters and presynaptic vesicle-mediated
release. Indeed, we have demonstrated that in vitro exposure to Tat inhibits DA
uptake via the vesicular monoamine transporter-2 (Midde et al., 2012), which is
responsible for monoamine storage and the vesicle-mediated DA release.
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Therefore, a very complex influence of Tat protein on the DA system should be
taken into consideration when we evaluate the actual DA levels in iTat-tg mice
after Dox-induced Tat expression. Given that the DA content reflects the tissue
levels of total DA rather than the specific extracellular DA levels, monitoring
release and uptake dynamics of endogenous DA levels in iTat-tg mice by an
electrochemical technique (e.g. fast scan cyclic voltammetry) is an interesting
topic for future investigation.
Another important finding from the current study is that the inhibitory
effects of Tat on the kinetic parameters of DA uptake through DAT/NET and the
respective substrate binding sites are selective to the PFC. There are several
possible explanations for our observations. First, compared to the PFC, the
striatum and hippocampus exhibit a higher density of DAT and NET (Horn,
1973b; Raiteri et al., 1977; Borgkvist et al., 2012), which may provide protection
from the acute inhibitory effects of HIV-1 Tat on transporter function. Second,
HIV-1 Tat may be not expressed throughout different brain regions. Although a
previous report showed Tat immunoreactivity was expressed throughout brain of
the Tat transgenic mice (Carey et al., 2012), the exact concentration of biological
Tat in these brain regions remains unclear. Indeed, our previous study has
reported that HIV-1 Tat inhibits DAT function in a concentration-dependent
manner (Zhu et al., 2009b). Third, with regards to HIV-1 Tat-induced decrease in
DA transport through NET, the NET in the PFC is more concentrated than the
DAT and plays a primary role in reuptake of DA (Moll et al., 2000; Moron et al.,
2002). For these reasons, it is possible that HIV-1 Tat-induced dysfunction of the
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DA system in the PFC could be mediated by inhibition of both DAT and NET. In
the early stages of HIV-1 infection, the cognitive impairments associated with the
PFC is initially observed (Everall et al., 1991; Melrose et al., 2008), whereas the
severe damage such as degradation of the dopaminergic terminals is observed
in the striatal area in the late stages of HIV-1 infected patients (Wang et al.,
2004; Chang et al., 2008). Moreover, volume loss and thinning of the PFC are
found in the patients with AIDS, which is associated with the severity of cognitive
impairments (Thompson et al., 2005), suggesting that the PFC is more
vulnerable to HIV infection compared to other regions. Thus, the current findings
demonstrate that the inhibition of DAT/NET specifically in the PFC may play an
important role in mediating Tat-induced neurocognitive impairment observed in
HAND”.
Whole-cell patch clamp recordings show that the evoked basal action
potential firing from layer V pyramidal neurons of the prelimbic cortex is reduced
in iTat-tg mice treated with Dox compared to saline controls. This reduced
neuronal firing is unlikely to have resulted from the Tat-induced decrease in DA
uptake via DAT and NET since DA at the low concentration used in our
experiments has no effect on action potentials and previous studies indicate that
higher concentrations of DA increase membrane excitability in striatal as well as
prefrontocortical projection neurons (Hopf et al., 2003; Ortinski et al., 2015;
Buchta et al., 2017; Lahiri and Bevan, 2020). Conversely, reduced neuronal firing
is unlikely to have caused a deficit in DAT function via effects on membrane
potential, since membrane hypoexcitability has been linked to surface expression
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of DAT (Richardson et al., 2016). Finally, DAT-mediated translocation of Na+ ions
across the plasma membrane is not expected to have a pronounced impact on
either the membrane potential or spike firing and a trend towards reduced action
potential firing with desipramine of AMPA-mediated currents and voltage-gated
Ca2+ channels (Koncz et al., 2014). Together, these observations suggest that
decreased action potential firing of prelimbic cortex pyramidal neurons in iTat-tg
mice is not directly related to Tat effects on DA transport. HIV-1 Tat may,
however, affect action potential generation through mechanisms independent of
DA uptake with a variety of bi-directional effects reported by previous studies
(Krogh et al., 2014; Ngwainmbi et al., 2014; Francesconi et al., 2018; Mohseni
Ahooyi et al., 2018).
In conclusion, the current findings provide a novel evidence that HIV-1 Tat
protein decreases the Vmax pf [3H]DA uptake and the respective substrate binding
sites in the PFC of iTat-tg mice by inhibiting both DAT and NET, which may have
important implications for preclinical studies if the role of the prefrontal DAT/NET
in neurocognitive impairment observed in HAND. Considering HIV-1 Tat
interacting with allosteric modulatory binding sites on these transporters (Zhu et
al., 2011; Sun et al., 2017), the current study provides a biological basis for
developing allosteric modulators that specifically block Tat binding on these
transporters with minimal effect on physiological DA transport, which may have
potential for therapeutic application in Tat-induced dysregulation of dopaminergic
transmission and its associated cognitive deficits observed in HIV-1 infected
patients.
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CHAPTER 4
Y88F MUTANT DOPAMINE TRANSPORTER EXPRESSING MICE
ATTENUATE HIV-1 TAT-MEDIATED INHIBITION OF DOPAMINE UPTAKE
AND LEARNING AND MEMORY DEFICITS IN A TRANSGENIC MOUSE
MODEL3

3

Strauss, M., McQuillen, P. Xiao, Z., Farmaki, E., & Zhu, J (2020). Y88F mutant
dopamine transporter expressing mice attenuate HIV-1 Tat-mediated inhibition of
dopamine uptake and learning and memory deficits in a transgenic mouse model. In
preparation for submission to The Proceeding of the National Academy of Sciences.
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ABSTRACT: Abnormal dopaminergic transmission has been implicated in the
neuropathogenesis of HIV-associated neurocognitive disorders. Inducible HIV-1
trans-activator of transcription (Tat) transgenic (iTat-tg) mice display deficits in
learning and memory similar to those observed in HAND patients. We previously
reported that dopamine (DA) uptake through the DA transporter (DAT) in the
prefrontal cortex (PFC) is significantly reduced in these mice. Furthermore, our
previous in vitro work has demonstrated that HIV-1 Tat inhibits the DAT through
a direct allosteric interaction with specific residues on the DAT, and that mutation
of these residues can attenuate HIV-1 Tat-mediated inhibition. In order to
determine if this phenomenon could be replicated in vivo, and to examine the
extent to which attenuation of HIV-1 Tat-mediated inhibition of the DAT would
prevent the cognitive deficits observed in these mice, we generated a mutant
tyrosine88 to phenylalanine (Y88F) DAT expressing mouse model. The Y88F
DAT mice do not demonstrate any baseline differences in [ 3H]DA uptake,
[3H]WIN 35,428 binding, total DAT expression, or locomotor activity compared to
WT DAT controls, except for a small increase in DA uptake affinity in the
striatum. This mouse line was crossed with the iTat-tg mice resulting in a model
which is capable of biologically expressing HIV-1 Tat and also possesses the
mutant Y88F DAT mutant (iTat-tg/Y88F). In contrast to the iTat-tg/WT mice, the
iTat-tg/Y88F mice did not demonstrate any reduction in DA uptake through DAT
in the PFC, or deficits in the acquisition of Novel object recognition. Our findings
indicate that preventing the HIV-1 Tat/DAT interaction, via a single point mutation
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on the DAT, is sufficient to attenuate HIV-1 Tat-mediated inhibition of DAT in the
PFC and learning and memory deficits previously observed in this mouse model.
4.1 INTRODUCTION
Despite the widespread use of efficacious combinatorial antiretroviral
therapy (cART) to control peripheral HIV infection and improve and extend the
lives of Human Immunodeficiency Virus (HIV) patients, HIV-associated
neurocognitive disorders (HAND) continue to remain prevalent and pose a
significant health problem.

HAND constitutes a

group of

neurological

complications including cognitive dysfunction, motor deficits, and dementia
(Heaton et la., 2010). These disorders manifest largely because most cART
medications do not cross the blood-brain barrier, while infected macrophages
carrying the virus can (Buckner et al., 2006), leaving the central nervous system
(CNS) as a reservoir for HIV viral replication (Valcour et al., 2012). Considerable
evidence has demonstrated that this long-term viral protein exposure can
accelerate damage to the mesocorticolimbic dopamine (DA) system (Nath et al.,
1987; Berger and Arendt, 2000; Koutsilieri et al., 2002; Wang et al., 2004).
Furthermore, converging lines of clinical observations, supported by imaging
(Wang et al., 2004; Chang et al., 2008), neuropsychological performance testing
(Kumar et al., 2011; Meade et al., 2011), and postmortem examinations (Gelman
et al., 2012), have demonstrated that DA dysregulation is correlated with the
abnormal neurocognitive function observed in HAND (Berger and Arendt, 2000;
Purohit et al., 2011). Among HIV viral proteins, the trans-activator of transcription
(Tat) protein has been demonstrated to play a central role in the neurotoxicity
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and cognitive impairment evident in HAND (King et al., 2006), and has been
detected in DA-rich brain areas (Gray et al., 2014), as well as in the cerebral
spinal fluid of patients diagnosed with HAND (Hudson et al., 2000), even those
receiving cART (Johnson et al., 2013).
The inducible HIV-1 Tat transgenic (iTat-tg) mouse has been utilized as a
clinically relevant model of symptomatic HAND, as it recapitulates many aspects
of the neuropathologies and neurocognitive impairments observed in the human
population (Kim et al., 2003; Carey et al., 2012). Our recent work (Strauss et al.,
2020) has revealed that this mouse model also demonstrates the characteristic
dysregulation of the dopaminergic system observed in HAND, specifically
through inhibition of the DA transporter (DAT) in the prefrontal cortex (PFC).
DAT-mediated DA reuptake is critical for maintaining normal DA homeostasis.
Human DAT (hDAT) activity is strikingly reduced in HIV-1-infected patients,
particularly those with a history of cocaine abuse, correlating with the severity of
HIV-1 associated cognitive deficits (Wang et al., 2004; Chang et al., 2008). Our
previous in vitro work has shed light on the molecular mechanism of HIV-1 Tatmediated inhibition of DAT-mediated DA uptake (Midde et al., 2013; Midde et al.,
2015; Quizon et al., 2016). Through a computational modeling and experimental
validation approach we have shown HIV-1 Tat inhibits DAT activity through a
direct allosteric interaction involving several distinct residues on the DAT. One
specific residue we have identified is DAT Tyrosine88 (Y88). We demonstrated
that mutation of this residue from a tyrosine to a phenylalanine (Y88F) did not
alter basal transporter function or expression (Midde et al., 2015) in vitro.
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Furthermore, this mutation was capable of attenuating the inhibitory effects of
recombinant HIV-1 Tat on DAT-mediated DA uptake through the disruption of a
hydrogen bond between this residue and HIV-1 Tat lysine19.
These findings raise two critical questions. First, could the ability of the
Y88F DAT mutant to attenuate HIV-1 Tat-mediated inhibition of DA uptake be
replicated in the iTat-tg mouse model? And second, what effect would this
attenuation have on the cognitive deficits observed in these mice? We have
generated a mouse model which genetically expresses a mutant Y88F DAT. The
Y88F DAT mouse line was then crossed with the iTat-tg mouse line to generate
mice which expressed the Y88F DAT mutation, and were also capable of
inducible HIV-1 Tat expression (iTat-tg/Y88F). This mouse line was used in the
current study to answer these questions.
4.2 MATERIALS AND METHODS
4.2.1.1 Animals
Four distinct mouse lines were used in the current investigation and are
abbreviated throughout the manuscript as follows: C57BL/6J mice, obtained from
Jackson laboratories, referred to as C57; Y88F+/+ homozygous DAT mice which
were generated from a C57 background and developed as described below,
referred to as Y88F; the inducible HIV-1 Tat transgenic mouse line, originally
developed by Dr. Johnny He, referred to as iTat-tg/WT, and the mouse line which
was generated by crossing the iTat-tg and Y88F mouse lines and contains the
components of both, referred to as iTat-tg/Y88F.
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Mice used for all experiments were between the age of 9-14 weeks. Mice
were housed (4-5 mice/cage) in a temperature (21 ± 2 °C)- and humidity (50 ±
10%)-controlled vivarium, which were maintained on a 12:12 h light/dark cycle
(lights on at 07:00 h) with ad libitum access to food and water. Animals were
maintained in accordance with the Guide for the Care and Use of Laboratory
Animals under the National Institute of Health (NIH) guidelines in the Assessment
and Accreditation of Laboratory Animal Care accredited facilities.

The

experimental protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of South Carolina, Columbia.
4.2.1.2 Y88F DAT mice
Heterozygous Y88F dopamine transporter (DAT) mutant mice were
originally generated by Ingenious targeting laboratory (Ronkonkoma, NY) utilizing
an embryonic stem cell targeting approach which is detailed in the results section
“Generation of a mutant Y88F DAT mice”. The heterozygous F1 mice generated
by Ingenious were transferred to the animal vivarium at the University of South
Carolina, where they were subsequently mated to generate homozygous Y88F
mice (Y88F+/+). The identification of Y88F+/+ mice was determined by PCR which
is described below.
4.2.1.3 iTat-tg mice
Male iTat-tg mice breeding stock were provided by Dr. Jay P. McLaughlin
at the University of Florida College of Pharmacy (Gainesville, FL). Mice in this
colony were established from progenitors originally derived by Dr. Johnny J. He
(Kim et al., 2003), currently at the Rosalind Franklin University of Medicine and
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Science (Chicago, IL). The iTat-tg mouse line genetically expresses a
“tetracycline-on (TETON)” system, which is integrated into the regulator for the
astrocyte-specific glial fibrillary acidic protein (GFAP) promoter and coupled to
the Tat1-86 coding gene, allowing astrocyte (brain)-specific Tat1-86 expression
induced by doxycycline (Dox) administration (Kim et al., 2003).
4.2.1.4 iTat-tg/Y88F mice
The hybrid iTat-tg/Y88F mice were generated by crossing the two mouse
lines described above. A detailed explanation of this process is outlined in the
Results section “Generation of mutant Y88F DAT mice” and the detailed PCR
protocol is outlined in the “PCR genotyping” section of the Materials and Methods
section.
4.2.2 PCR
The PCR protocols for identification of homozygous Y88F (+/+) mice were
adapted from the procedures given to us from Ingenious at the time we received
the founding six animals. PCR testing for the iTat-tg transgenes was adapted
from the original description of this transgenic mouse line (Kim et al., 2003). Each
mouse was ear-tagged and tail-clipped between three and four weeks of age.
The tail clip was placed into a tube containing 200 µL of tail buffer (10mM Tris
HCl, 100mM NaCl, 10mM EDTA, 0.5% SDS) which contained 0.75 mg/mL of
proteinase K. The tails in solution were placed in a 56 °C water bath overnight.
The following morning the samples were heated to 95 °C on a dry heater for 5
minutes to deactivate the proteinase K. The samples were then spun down to
pellet any undissolved tissue, and these samples were subsequently utilized for
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PCR analysis. To test the zygosity of the Y88F mutation, 1 µL of sample was
placed into 23 µL of PCR solution which contained 10.47 µL of ddH2O, 6.5 µL
Betaine, 0.325 µL DMSO, 2.5 µL 10X PCR buffer, 2 µL MgCl 2, 0.5 µL of 200 µM
dNTPs, 0.5 µL of 100 µM primer mix (FWD, NDEL1: 5’ – ACT CAG GGG TGC
AGT GGA GG – 3’ and RVS, NDEL2: 5’ – AAG CAG CCC CAC TAT CCT ACA
GG – 3’), and 0.2 µL of Taq polymerase. This solution was ran using the
following PCR parameters: 94 °C for 3 min once, followed by 30 cycles of 94 °C
for 30 sec, 60 °C for 30 sec, and 72 °C for 1 min, then held at 4 °C until ready to
load into a gel. The resulting PCR samples were loaded into a 2% agarose gel
and ran on 80V for 30 min. A band at 420 bp was associated with WT DAT and a
band at 522 bp was associated with the Y88F mutation. Therefore, if only one of
the bands was present the mouse was determined to be homozygous (-/- if at
420 and +/+ if at 522) for the Y88F mutation or if both bands were present the
mouse was determined to be heterozygous for the mutation (see figure 4.1A for
example). These mice were additionally tested to verify that a TAC to TTC point
mutation was introduced. For this PCR the following conditions were utilized: 1
µL of sample was placed into a PCR tube with 19 µL of PCR solution which
contained 11.25 µL of ddH2O, 4 µL of PCR buffer, 2 µL of MgCl2, 0.5 µL of 200
µM dNTPs, 1 µL of 100 µM primer mix (FWD, SQ1: 5’ – GGG ACC AAT GTC
TTC TGT GG – 3’ and RVS, RNEOGT: 5’ – GAA AGT ATA GGA ACT TCG CGA
CAC GGA C – 3’), and 0.25 µL of Taq Flex polymerase. This solution was ran
using the following PCR parameters: 94 °C for 3 min once, followed by 30 cycles
of 94 °C for 30 sec, 55 °C for 30 sec, and 72 °C for 1 min, then held at 4 °C until
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ready to load into a gel. The resulting PCR samples were loaded into a 2%
agarose gel and ran on 80V for one hour. A band at 771 bp indicated that the
point mutation was present (see figure 4.1B for example).
Once homozygous Y88F (+/+) mice were obtained we began to cross this
line with the iTat-tg mice as described in the Results section “Generation of
mutant Y88F DAT mice”. The efficacy of PCR primers to detect the presence of
the Teton-GFAP and TRE-Tat86 transgenes was tested using the following PCR
parameters: 1 µL of sample was placed into a PCR tube with 19 µL of PCR
solution which contained 11.25 µL of ddH2O, 4 µL of PCR buffer, 2 µL of MgCl2,
0.5 µL of 200 µM dNTPs, 1 µL of 100 µM primer mix (Teton-GFAP FWD: 5’ –
GCT CCA CCC CCT CAG GCT ATT CAA – 3’ and RVS: 5’ – TAA AGG GCA
AAA GTG AGT ATG GTG 3’; and TRE-Tat86 FWD: CGG TGG GAG GCC TAT
ATA AGC 3’, and RVS: 5’ – AAC TGC AGT TAT TCC TTC GGG CCT GTC GG –
3’), and 0.25 µL of Taq Flex polymerase. This solution was ran using the
following PCR parameters: 94 °C for 3 min once, followed by 30 cycles of 94 °C
for 30 sec, 55 °C for 30 sec, and 72 °C for 1 min, then held at 4 °C until ready to
load into a gel. The resulting PCR samples were loaded into a 2% agarose gel
and ran on 80V for one hour. A band at 250 bp indicated the presence of the
TRE-Tat86 gene and a band at 420 bp indicated the presence of the TetonGFAP gene (see figure 4.3A/B for example). Following initial testing the levels of
gene expression were determined using qPCR. 0.5 µL of tail sample was placed
into a 384 well plate which also contained 4.95 µL of 2XSYBR Green Mix, 0.5 µL
of 10 µM Primer mix (as noted above for PCR) and 3.95 µL of ddH2O. The plate
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was then sealed with plastic, spun down, and ran using the following parameters:
Initial denaturation at 94 °C for 2 min followed by 40 cycles of 94 °C for 15 sec
and 60 °C for 1 min. Results were interpreted using CFX manager software and
were compared to iTat-tg mouse transgene expression levels using the ΔΔCq
calculation method. Mice which expressed both transgenes at similar levels as
the iTat-tg/WT mice were considered to have adequate expression levels of
these genes to be used for breeding/experimentation.
4.2.3 Drug administration and Synaptosomal preparation
Male iTat-tg, C57BL/6J, Y88F, and iTat-tg/Y88F mice were administered
either Dox (100 mg/kg/day) or saline (10 μl/gram body weight) via intraperitoneal
injection for 7 consecutive days. The optimized dose of Dox was chosen because
it has been previously proven efficacious for induction of Tat (Zou et al., 2007;
Carey et al., 2012; Paris et al., 2014b) and findings showing that iTat so induced
is biologically active during the period of behavioral testing (Zou et al., 2007).
The 7-day Dox or saline treatment paradigm was chosen for the kinetic analysis
of DA uptake and behavioral testing based on the previous physiological and
behavioral studies (Strauss et al, 2020; Carey et al., 2012). Selection of animals
for saline or Dox treatment was made randomly among littermates.
All mice were rapidly decapitated 24 h after last saline or Dox injection.
Brain tissue dissected from prefrontal cortex (PFC, prelimbic and infralimbic
cortices combined) and striatum, and was pooled from a group of three mice for
[3H]DA uptake and [3H]WIN 35,428 binding (constituting a single sample for each
region), which was used as a single replicate (n) for conducting independent
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experiments. Thus, “n” refers the number of independent experiments conducted,
rather than the number of mice used. Synaptosomes were prepared using our
published method (Strauss et al., 2020). The PFC region was a focus of the
current study because it is a critical brain region for higher cognitive function
(Miller and Cohen, 2001; Dalley et al., 2004; Ridderinkhof et al., 2004). Given
that DA uptake through DAT is not identical throughout various brain regions, the
DA uptake through DAT in striatum was examined in addition to the PFC. The
striatum was also selected due to its central role in DA neurotransmission. The
tissue was homogenized immediately in 20 mL of ice-cold 0.32 M sucrose buffer
containing 2.1 mM of NaH2PO4 and 7.3 mM of Na2HPO4, pH 7.4; with 16 up-anddown strokes using a Teflon pestle homogenizer (clearance approximately 0.003
in.). Homogenates were centrifuged at 1,000g for 10 min at 4°C and the resulting
supernatants were then centrifuged at 12,000g for 20 min at 4°C. The resulting
pellets were resuspended in the respective buffer for each individual assay as
noted below.
4.2.4 Kinetic analysis of synaptosomal [3H]DA uptake assay
To determine the effects of the mutant Y88F DAT on DA uptake compared
to WT DAT, and to assess if this mutation would result in attenuation of HIV-1
Tat-mediated inhibition of DA uptake via DAT in the PFC, the maximal velocity
(Vmax) and Michaelis-Menten constant (Km) of synaptosomal [3H]DA uptake were
examined using a previously described method (Strauss et al., 2020). Because
DA is transported by DAT, NET, and SERT in the PFC (Moron et al., 2002;
Williams and Steketee, 2004), kinetic analysis of [3H]DA uptake via DAT in the
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PFC was assessed in the presence of desipramine (1 µM) and fluoxetine (0.1
µM) to prevent DA uptake into norepinephrine- and serotonin-containing nerve
terminals, respectively. In brief, the resulting pellets described above were
resuspended in Krebs-Ringer-HPES assay buffer (125mM NaCl, 5mM KCl,
1.5mM MgSO4, 1.25mM CaCl2, 1.5mM KH2PO4, 10mM glucose, 25mM HEPES,
0.1mM EDTA, 0.1mM pargyline and 0.1mM L-ascorbic acid, saturated with 95%
O2 ⁄ 5% CO2, pH 7.4). Aliquots of synaptosomal tissue (50μg/25 µL) were
incubated with one of 6 mixed [3H]DA concentrations containing a range of DA
concentrations (1nM - 1µM) and fixed [3H]DA (12nM) for 8 minutes at 37 °C.
Incubation was terminated by the addition of 3mL of ice-cold assay buffer,
followed by immediate filtration through Whatman GF/B glass fiber filters
(presoaked with 1mM pyrocatechol for 2h). Filters were washed three times with
3mL of ice-cold assay buffer using a Brandel cell harvester (Model MP-43RS;
Biochemical Research and Development Laboratories Inc., Gaithersburg, MD).
Radioactivity was determined by liquid scintillation spectrometry (Model
B1600TR, Packard Corporation Inc., Meriden, CT). Bovine serum albumin was
used as a standard (Bradford, 1976) to measure protein concentration for all
samples. Nonspecific uptake of [3H]DA into DAT

was determined in the

presence of 10 μM Nomifensine.
4.2.5 [3H]WIN 35,428 binding
[3H]WIN 35,428 represents the substrate binding site on the DAT. To
determine the effects of the mutant Y88F DAT on substrate binding sites
compared to WT DAT, [3H]WIN 35,428 binding was examined using our
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previously described method (Strauss et al., 2020). Saturation binding assays
were conducted in duplicate in a final volume of 250 μL for PFC, striatum. 50 μL
aliquots (50 μg protein) of synaptosomes were incubated in 0.32M sucrose buffer
(pH: 7.4) containing 2.1 mM NaH2PO4 and 7.3 mM Na2HPO4 with six
concentrations of [3H]WIN 35,428 (1, 5, 10, 15, 25, 30 nM) on ice for 2 h.
Desipramine (1 µM) was included to inhibit [3H]WIN 35,428 binding to the NET in
the PFC. Nonspecific binding was determined in the presence of 10 µM cocaine
in the striatum and 10 µM nomifensine in the PFC. The reaction was terminated
by rapid filtration onto Whatman GF/B glass filter filters, presoaked for 2 h with
assay buffer containing 10% polyethylenimine, through a Brandel cell harvester
(Model MP-43RS; Biochemical Research and Development Laboratories Inc.,
Gaithersburg, MD). Filters were washed three times with 3 mL of ice-cold assay
buffer. Radioactivity was determined by liquid scintillation spectrometry (Model
B1600TR, Packard Corporation Inc., Meriden, CT), and bovine serum albumin
(Sigma-Aldrich; St. Louis, MO) was used as a standard (Bradford, 1976) to
measure protein concentration for all samples.
4.2.6 Western blotting
Synaptosomal preparations which were used for DA uptake were stored at
-80 with protease inhibitors and subsequently thawed and subjected to gel
electrophoresis and western blotting to obtain immunoreactive DAT bands.
Samples were separated by 10% SDS-polyacrylamide gel electrophoresis for
~90 min at 125V. Samples were then transferred to Immobilon-P transfer
membranes (0.45 µm pore size) in transfer buffer (50 mM Tris, 250 mM glycine,
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3.5 mM SDS) using a Mini Trans-Blot Electrophoretic Transfer Cell for 90 min at
75 V. The membranes were then incubated with blocking buffer (5% milk powder
in PBS containing 0.5% Tween-20) for 1 h at room temperature, followed by
incubation with either goat anti-DAT (Santa Cruz, C-20 polyclonal antibody,
diluted 1:500 in blocking buffer) overnight at 4 °C. Transfer membranes were
then washed three times with blocking buffer at room temperature followed by
incubation with anti-goat-HRP (Jackson Laboratory, catalog number 305-035-045
diluted 1:10,000 in blocking buffer) for 1 h at room temperature. Membranes
were then washed an additional three times in PBS containing 0.5% Tween-20
(Sigma-Aldrich; St. Louis, MO). Immunoreactive proteins on the transfer
membranes were detected using Amersham ECL prime western blotting
detection reagent (GE life sciences; Chicago, IL) and developed on Hyperfilm
(GE life sciences; Chicago, IL). After detection and quantification of DAT, each
blot was washed and re-probed with rabbit anti-Calnexin (Santa Cruz,
Biotechnology, catalog number SC-11397 polyclonal antibody, diluted 1:10,000
in blocking buffer), an endoplasmic reticular protein, to monitor protein loading
between all groups. Multiple autoradiographs were obtained using different
exposure times, and immunoreactive bands within the linear range of detection
were quantified by densitometric scanning using Scion image software. Band
density measurements, expressed as relative optical density, were used to
determine levels of DAT.
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4.2.7 Behavioral Assays
4.2.7.1 Locomotor activity
As locomotor activity in mice is dependent on both motivation and
movement capability, which may be impacted by the dopaminergic system,
locomotor activity was compared between Y88F and WT (C57BL/6J) mice to
determine if the Y88F DAT mutation had any effect on this outcome. The activity
monitors were 16” x 16” square plexiglass chambers that detect free movement
of animals by infrared photocell interruptions. This equipment uses an infrared
photocell grid with 32 emitter/detector airs to measure locomotor activity. All
activity monitors are located in an isolated room located within the University of
South Carolina vivarium. Mice were habituated to the locomotor activity
chambers (San Diego Instruments) for two 60-min sessions once/day prior to
testing. Twenty four hours after the second habituation session, all mice were
placed into the chamber for a 60 minute session where activity was recorded and
is reported as total horizontal activity.
4.2.7.2 Novel Object Recognition
Learning and memory performance was examined using the novel object
recognition (NOR) assay adapted from a previous report (Carey et al., 2012).
The NOR task for mice is based on their tendency to spontaneously explore their
environment; unaffected animals will spend more time exploring a novel object
than a familiar one (Frick and Gresack 2003). This task does not require
motivation such as food or water deprivation and minimizes external and physical
stressors. The NOR task probes both learning and memory function, as the final
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output of the assay is affected by both. The paradigm was carried out over three
phases as described in Carey et al. 2012. Each phase lasted 10 min with a 10
min inter-trial interval (ITI). During each phase, mice freely explored the
environment before being returned to their home cages. During phase 1, objects
A and B (e.g., pair of dice) were centered across from each other in a rectangular
cage (which was identical to the home cage except that it was placed inside of a
brown cardboard box to decrease distraction), 2 cm away from the walls. In
phase 2, object B was moved laterally to 1 cm from the edge of the cage
whereas object A remained fixed. In phase 3, after completion of the training
phases, object B (the die) was replaced with a novel object (a marble). Note that
phase 2 served as a control, to demonstrate that subsequent performance in
phase 3 was based on novel object recognition, rather than simple changes in
object location. In contrast, phase 3 testing assessed both learning and memory,
as mice will typically recognize and reject previously encountered objects to
spend more time with the novel object Carey et al., 2009. Use of marbles and
dice as novel objects was randomized across the study. For each phase, the
time mice spent attending to each object was video recorded and analyzed by a
blinded team member with a stopwatch. Object attending was defined as the
duration of time a mouse spent in physical contact with the object, using any
body part other than the tail, or whenever it was within 0.5 cm of the object,
facing it, and engaged in active exploration (e.g., sniffing or manipulating). Data
are presented as a percent recognition index (RI) for object B: RI = (time
attending to object B/time attending to object A+B)*100.
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4.2.8 Statistical analysis
Data are expressed as means ± S.E.M., and n refers to the number of
individual experiments for each group. To analyze the kinetic parameters
(Vmax/Km and Bmax/Kd) of [3H]DA uptake or [3H]WIN 35,428, best-fit nonlinear
regression analysis using a single-site model was conducted for each individual
experiment using GraphPad Prism 8 software. The kinetic parameters were then
compared between either the WT (C57) and Y88F DAT expressing mice, the
saline- and Dox-treated iTat-tg/Y88F mice, or the iTat-tg/WT mice using unpaired
Student’s t tests, which were conducted using IBM SPSS statistics version 25.
Analyses resulting in P < 0.05 were considered significant.
4.3 RESULTS
4.3.1 Generation of mutant Y88F DAT mice
Heterozygous Y88F dopamine transporter (DAT) mutant mice were
originally generated by Ingenious targeting laboratory (Ronkonkoma, NY) utilizing
an embryonic stem cell targeting approach. This technique consisted of six
distinct steps in order to generate the mutant mouse model (Figure 4.1A). First, a
DNA construct was designed targeting a short homology arm of slc6a3 gene,
which was suitable for PCR amplification and placement of the Neo cassette
(Figure 4.1B). The construct was designed to create a point mutation of the TAC
codon (correlating to tyrosine 88 of DAT) to TTC (Phenylalanine). This construct
was generated using homologous recombination, which is ideal for creating
single point mutations with a low risk of unwanted mutations. Second, the DNA
construct was electroporated into mouse embryonic stem (ES) cells, which were
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Figure 4.1 Generation of mutant Y88F DAT mouse model and PCR genotyping.
(A) Schematic representation of the embryonic stem cell/blastocyst approach
used by Ingenious Targeting Laboratory to generate heterozygous Y88F DAT
expressing mice. (B) A 7.5 kb genomic region was first sub cloned from a
positively identified C57BL/6 BAC clone (RP23-433L1) using a homologous
recombination-based technique. The region was designed such that a long
homology arm (LA) extends ~4.6 kb 5’ to a codon exchange TAC>TTC (Tyrosine
to Phenylalanine). A Neo cassette is positioned 471bp (MA; middle arm)
downstream of the TTC codon. A short homology arm (SA) extends ~ 2.5 kb
downstream of the Neo cassette. NDEL1 and NDEL2 represent the targets of the
forward and reverse primers, respectively, which used to screen for deletion of
the Neo cassette, and allow for determination of homo/heterozygosity. SQ1 and
RNEOGT represent the targets of the forward and reverse primers, respectively,
used to verify the presence of the point mutation. (C) Representative result of
PCR gel exposure (gel red) using the NDEL1/NDEL2 primer combination. A band
at 420 bp only indicates a homozygous WT mouse (example #K116), a band at
522 bp only represents a homozygous Y88F mouse (example #K115), and the
presence both bands indicates a heterozygous mouse (example #K111). (D)
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Representative result of PCR gel exposure (gel red) using the SQ1/RNEOGT
primer combination. A band at 771 kb indicates the presence of the point
mutation (#207-213) or the lack thereof (example 189, negative control). Primer
sequences are shown in the PCR section of the materials and methods.

then selected based on integration of the Neo cassette into the mouse genome.
The DNA from the selected ES cells was extracted and provided to the screening
team for vector integration screening. Third, the screening team analyzed DNA
samples by optimized PCR to identify potential positive clones and subsequent
qPCR was used to assess copy number of the targeted allele. The positive ES
cell clones were expanded, and genotyping was reconfirmed. Fourth, the
reconfirmed clones were microinjected into mouse host blastocysts (3.5-day old
mouse embryos) and the injected blastocysts were subsequently transferred into
foster moms (pseudo-pregnant females). Fifth, the chimeric (F0) mice produced
from the transferred embryos were assessed by coat color and medium- and
high-percentage chimera mice were mated with WT mice to produce the F1
mice. Finally, tail clip DNA from F1 mice were genotyped to determine germline
transmission of the target allele (heterozygous). These heterozygous F1 mice
were transferred to the animal vivarium at the University of South Carolina. At
this time, the heterozygous Y88F mice were mated together and screened for
zygosity (Figure 4.1C) and presence of the point mutation was verified (Figure
4.1D). Homozygous mice with confirmed point mutation were mated to create a
stable line of homozygous Y88F mice.
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4.3.2 Y88F DAT mutant mice do not display baseline differences in dopaminergic
function
DAT Tyrosine 88 (Y88) has been suggested to play a role in maintaining a
conformational structure of the DAT which is prepared for conformational
conversion associated with DA uptake. This role is supported by stabilization of
transmembrane helix 1b (TM1b) and transmembrane helix 6a (TM6a) through
hydrophobic or electrostatic intramolecular interactions (Midde et al., 2015).
Additionally, the aromatic side chain of Y88 is sandwiched between TM1b and
extracellular loop 4 (EL4) in a hydrophobic region. These insights indicate that
mutation of Y88 to a phenylalanine (Y88F) would not be expected to have a
significant effect on the function of the DAT. Our previous report (Midde et al.,
2015) examined this mutation in hDAT expressing PC12 cells and found no
significant alterations in DA uptake or total/surface expression of DAT. We did
report small alterations in the affinity of WIN 35,428 binding, as well as substrate
(DA) and inhibitor (cocaine) potencies, which may be due to slight conformational
alterations near the primary substrate (S1) binding site. Taken together these
results indicate that Y88F mutation to hDAT maintains relatively normal
transporter function. In order to verify if similar results could be produced in the
Y88F expressing mice, we performed [3H]DA uptake, [3H]WIN 35,428 binding,
and examination of total protein expression in the prefrontal cortex (PFC) and
striatum of these mice compared to WT DAT controls (C57). As shown in Table
4.1, we did not find any significant differences in the Vmax or Km of [3H]DA uptake,
the Bmax or Kd of [3H]WIN 35,428 binding, or total DAT expression in the PFC of
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Y88F DAT mice compared to WT controls. In the striatum, we did identify a 32%
increase in the Km of [3H]WIN 35,428 binding, indicating an increased affinity at
the S1 binding site, although no other significant differences were found. Finally,
we assessed locomotor activity in the Y88F DAT mice compared to WT controls
(Table 4.1), as locomotor activity is dependent on both motivation and movement
capability, which may be impacted by the dopaminergic system, and our results
demonstrate that the Y88F mice do not display any significant differences in this
behavioral outcome. Taken together our results indicate that the Y88F DAT mice
do not display significant alterations in DAT function, or the dopaminergic system
compared to WT expressing DAT control mice.
4.3.3 Generation of iTat-tg/Y88F mouse line
Our recent publication demonstrated that following 7-day dox treatment,
iTat-tg mice displayed a 27% reduction in the Vmax of [3H]DA uptake in the PFC
compared to saline treated controls (Strauss et al., 2020). Additionally, our
previous data has demonstrated that the Y88F DAT mutation is capable of
attenuating the inhibitory effects of HIV-1 Tat on DA uptake (Midde et al., 2015)
in vitro. Thus, the aim of our current work was to determine first, if the attenuation
of HIV-1 Tat-mediated inhibition of DAT observed in vitro could be replicated in
an animal model; second, to determine the extent to which the aforementioned
attenuation would prevent cognitive deficits previously reported in this mouse
model (Carey et al., 2012). To investigate these possibilities, the Y88F DAT
mutant mice were crossed with the iTat-tg mice to generate hybrid iTat-tg/Y88F
mice. Importantly, the iTat-tg mice require two distinct transgenes in order to
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Table 4.1 Summary of Vmax and Km of [3H]DA uptake, Bmax and Kd of [3H]WIN
35,428 binding, and total dopamine transporter expression in the prefrontal
cortex and striatum of C57BL/6J and Y88F mice
Prefrontal cortex

Striatum

Vmax
(pmol/min/mg)

Km (nM)

Vmax
(pmol/min/mg)

Km (nM)

C57BL/6J

1.34 ± 0.59

711 ± 307

47.0 ± 10

83 ± 6.1

Y88F

1.57 ± 0.28

794 ± 600

55.8 ± 6.2

110 ± 5.2*

Bmax
(pmol/mg)

Kd (nM)

Bmax
(pmol/mg)

Kd (nM)

C57BL/6J

0.514 ± 0.036

6.26 ± 0.68

36.2 ± 3.8

37.6 ± 2.6

Y88F

0.622 ± 0.086

9.62 ± 3.6

32.2 ± 2.2

33.1 ± 6.6

Dopamine transporter/Calnexin Expression (arbitrary units)
C57BL/6J

1.03 ± 0.13

1.23 ± 0.057

Y88F

0.729 ± 0.05

1.13 ± 0.076

Total horizontal activity (beam breaks)
C57BL/6J

7142 ± 723

Y88F

7737 ± 597

Data are expressed as mean ± S.E.M. values from three to four independent
experiments performed in duplicate. * p < 0.05, compared to C57BL/6J
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produce HIV-1 Tat expression following dox treatment, the Teton-GFAP gene,
which encodes the tetracycline-on system and is linked to glial fibrillary acidic
protein (GFAP) expression, and the TRE-Tat86 gene, which encodes the Tat1-86
protein (Kim et al., 2003). During the crossing of the two mouse lines the zygosity
of the Y88F DAT mutant was assessed as described in Figure 4.1, and the
presence of the Teton-GFAP and TRE-Tat86 genes was determined by PCR as
shown in Figure 4.2 (detailed in the materials and methods PCR section).
Importantly, as the number of copies of the Teton-GFAP and TRE-Tat86 genes
can vary between mice, qPCR was also used to ensure that the iTat-tg/Y88F
mice possessed similar levels of the transgenes as the iTat-tg/WT mice. The
crossing of these two mouse lines yielded iTat-tg/Y88F mice, which expressed
both the Y88F DAT mutant as well as the two transgenes required for HIV-1 Tat
expression.
4.3.4 iTat-tg/Y88F mice demonstrate attenuation of HIV-1 Tat-mediated inhibition
of DA uptake
To determine if the Y88F DAT mutation was capable of attenuating our
previously reported HIV-1 Tat-mediated inhibition of DA uptake through DAT in
the PFC (Strauss et al., 2020) we performed [3H]DA uptake following 7-day
administration of saline or dox to both iTat-tg/WT and iTat-tg/Y88F mice. This
experimental paradigm allowed us to investigate three key outcomes. First, we
determined that our previously reported data could be replicated, as we found a
significant reduction of 33% in the Vmax of [3H]DA uptake (Figure 4.3A) in the doxtreated iTat-tg/WT mice compared to the saline-treated controls [t(8) = 3.46, p <
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Figure 4.2 Representative PCR results for the TRE-Tat86 and Teton-GFAP
genes. (A) Example PCR result for TRE-Tat86 gene expression using the TRETat86 FWD and RVS primers. A band at 250 bp indicates the presence of the
gene (example #28) or a lack of a band indicates the gene is not present
(example #27). (B) Example PCR result for Teton-GFAP gene expression using
the Teton-GFAP FWD and RVS primers. A band at 420 bp indicates the
presence of the gene (example #31) or a lack of a band indicates the gene is not
present (example #28). The presence of both genes is required for the mice to
express the HIV-1 Tat protein following dox administration (example #31). Primer
sequences are shown in the PCR section of the materials and methods.
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A
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(pmol/min/mg)
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1.5
1.0
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iTat/Y88F

B

Vmax
Km
iTat/WT - Sal 1.42 ± 0.096 215 ± 53
iTat/WT - Dox 0.95 ± 0.095** 136 ± 23

Vmax
iTat/Y88F - Sal 1.27 ± 0.11
iTat/Y88F - Dox 1.36 ± 0.28

Km
283 ± 92
183 ± 19
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Figure 4.3 Kinetic analysis of synaptosomal [3H]DA uptake in the PFC of iTattg/WT and iTat-tg/Y888F mice following 7-administration of saline or Dox.
Synaptosomes were incubated with a range of mixed DA concentrations (0.03 –
1 µM, final concentration) containing a fixed concentration (12 nM) of [ 3H]DA.
The Vmax and Km values for [3H]DA uptake via DAT in the PFC of iTat-tg/WT (A)
and iTat-tg/Y88F (B) mice following 7-day administration of saline (black circles,
solid line) or Dox (white circles, dashed line) were calculated using non-linear
regression analysis with a one-site binding parameter and represent the means
from five independent experiments ± S.E.M. ** p < 0.01 compared to saline
control group.

115

0.01], which is similar to our previously reported decrease of 27%, with no
significant difference in Km. Additionally, we did not find any significant
differences between the saline- and dox-treated iTat-tg/WT mice in striatal Vmax
(saline: 37.6 ± 3.8; dox: 35.6 ± 1.5 pmol/mg/min) or Km (saline: 146 ± 7; dox: 145
± 13 nM), which is consistent with our previous study (Strauss et al., 2020).
Second, we did not find any significant differences in Vmax or Km between the
saline-treated iTat-tg/WT and saline-treated iTat-tg/Y88F in the PFC (Figure
4.3A/B) or striatum (iTat-tg/WT Vmax: 37.6 ± 3.8, iTat-tg/Y88F Vmax: 34.0 ± 4.6
pmol/mg/min; iTat-tg/WT Km: 146 ± 7, iTat-tg/Y88F Km: 182 ± 18 nM), confirming
that this mutation does not alter basal DA uptake capability. Finally, the observed
decrease in DA uptake in the iTat-tg/WT mice following dox treatment was not
observed in the iTat-tg/Y88F mice (Figure 4.3B). Taken together, this data
indicates that preventing the HIV-1 Tat/DAT interaction, via a single point
mutation on the DAT which does not alter basal uptake function, is sufficient to
prevent the inhibition of DAT function associated with HIV-1 Tat expression in
this mouse model.
4.3.5 iTat-tg/Y88F mice do not display learning and memory deficits observed in
iTat-tg/WT mice
Learning and memory capabilities were analyzed in the iTat-tg/WT and
iTat-tg/Y88F mice using the novel object recognition task (NOR). Both genotypes
were assessed following 7-day treatment with saline or dox immediately before
being used for [3H]DA uptake assays. Similar to the [3H]DA uptake experimental
design, the genotype/treatment groups used for NOR were analyzed for three
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key outcomes. First, we were able to replicate previously published data
demonstrating that iTat-tg/WT mice treated with dox for 7 days have impaired
novel object recognition (Carey et al., 2012), as demonstrated by the significant
difference in phase 3 recognition index (RI) compared to the saline-treated
controls (iTat-tg/WT-saline-phase 3: 71.5%; iTat-tg/WT-dox-phase 3: 53.9%; [t(22)
= 2.086, p < 0.05]). Importantly, the dox-treated iTat-tg/WT mice did not show an
increase in NOR performance when compared to their phase 1 RI (iTat-tg/WTdox-phase 1: 49.1%; p = 0.47), whereas their saline-treated counterparts did
(iTat-tg/WT-saline-phase 1: 54.3%; [t(26) = 2.427, p < 0.05]). Second, we did not
find any significant phase 3 RI differences between the saline-treated iTat-tg/WT
or iTat-tg/Y88F mice (iTat-tg/Y88F-saline-phase 3: 61.5%; p = 0.18), indicating
that the Y88F DAT mutation does not significantly alter NOR response. Finally,
the deficit in NOR acquisition identified in the dox-treated iTat-tg/WT mice was
not observed in the iTat-tg/Y88F dox-treated mice, as these mice did not show
any significant phase 3 RI differences compared to the saline-treated iTattg/Y88F controls (iTat-tg/Y88F-dox-phase 3: 62.6%; (p = 0.87), and both the
saline- and dox-treated iTat-tg/Y88F mice demonstrated an increase in NOR
performance compared to their phase 1 RI values (iTat-tg/Y88F-saline-phase 1:
50.3%; [t(35) = 2.196, p < 0.05] compared to phase 3; iTat-tg/Y88F-dox-phase 1:
51.1%; [t(33) = 2.194, p < 0.05] compared to phase 3). Taken together, this data
indicates that by preventing the HIV-1 Tat-mediated DAT inhibition, via Y88F
DAT mutation, is sufficient to prevent deficits in learning and memory associated
with the NOR task.
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Figure 4.4 iTat-tg/Y88F demonstrate attenuation of phase 3 novel object
recognition deficits observed in iTat-tg/WT mice. Following 7-day administration
of saline or dox iTat-tg/WT (Sal – white; Dox – light grey) and iTat-tg/Y88F (Sal –
medium grey; Dox – dark grey) were subjected to the novel object recognition
assay. The phase 3 recognition index was compared to the phase 1 recognition
index within each genotype/treatment group, and a p < 0.05 was considered
significant and is represented by *. Following this analysis, the phase 3
recognition index of the dox-treated iTat-tg/WT and iTat-tg/Y88F was compared
to the phase 3 recognition index of their respective controls. A p < 0.05 was
considered significant and is denoted by #. Data is presented as the mean ±
S.E.M. for the phase 3 recognition index calculated as time spent with the novel
object/ (time spent with novel object + original object) from n = 16-19 mice/bar).
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4.4 DISCUSSION
Through the use of the Y88F DAT mutant and inducible HIV-1 Tat
transgenic mouse models, the current study sought to determine the role of HIV1 Tat-mediated inhibition of DA uptake through DAT on the development of
cognitive deficits associated with HAND. This work built upon the findings of
several previous studies. First, that biological HIV-1 Tat expression inhibits the
DAT in the PFC of iTat-tg mice (Strauss et al., 2020), second, that these mice
also demonstrate learning and memory deficits similar to HIV-1 infected patients
(Carey et al., 2012), and third, that a tyrosine88 to phenylalanine (Y88F) mutation
on the DAT is capable of attenuating the HIV-1 Tat/DAT interaction in vitro
(Midde et al., 2015). Our results indicate, similar to previous in vitro reports
(Midde et al., 2015), that an in vivo Y88F DAT mutation does not significantly
alter DAT function or expression, as evidenced by no changes in [ 3H]DA uptake,
[3H]WIN 35,428 binding, total DAT protein expression, or locomotor activity
compared to WT DAT mice. Furthermore, when crossed with the Y88F DAT
mice, the iTat-tg mice no longer demonstrated inhibition of DA uptake through
DAT in the PFC or deficits in the NOR task, suggesting that HIV-1 Tat-mediated
inhibition of DAT may play a critical role in the development of cognitive deficits
associated with HAND.
The first aim of our study was to develop a mouse model which expressed
a Y88F DAT mutation. This was accomplished with a homologous recombination
technique in embryonic stem cells using a replacement type vector with a
selectable marker, allowing for the precise and specific mutation of a single

119

amino acid on a given protein (Rubinstein et al., 1993). Although the recent
advent of CRISPR/Cas9 has made gene editing in mammals a much more rapid
and inexpensive process, several concerns remain with this technique, primarily
off-target effects (Rodríguez-Rodríguez et al., 2019). Because CRISPR/Cas9 is
based on complementary target sequences only about 20 nucleotides in length,
the system allows for cleavage at genomic locations which are partially
complementary, creating the potential for mismatch pairings between the
organism’s DNA and the guide RNA (gRNA). These off-target cuts remain one of
the largest unresolved issues with the CRISPR/Cas9 system, and there is little
evidence as what the consequences of these off-target cuts may be (RodríguezRodríguez et al., 2019). In contrast, the technique used in this study to generate
the Y88F DAT mutant mice has little evidence of off-target effects (Friedrich and
Soriano, 1991), allowing us to examine the specific effects of this mutation on the
development of HAND, without concern of unwanted mutations.
The Tyrosine88 residue on the DAT was chosen based on our previous in
vitro reports (Midde et al., 2015; Sun et al., 2019) demonstrating mutation of this
residue to a phenylalanine does not substantially alter transporter function and
also attenuates HIV-1 Tat-mediated inhibition of DA uptake. In these in vitro
studies, the Y88F DAT mutation did not affect the Vmax or Km of [3H]DA uptake,
but did decrease the Bmax and increase the Kd of [3H]WIN 35,428 binding without
alterations in DAT surface expression, suggesting that this mutation may alter the
substrate binding site. This data is consistent with the role of Tyrosine88 in the
structure and function of the DAT. Tyrosine88 is located in transmembrane helix
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1 (TM1) of the DAT which plays an important role in mediating the structural
environment surrounding the DA binding site (Cheng and Bahar, 2019).
Specifically, a nearby hydrophobic cluster is essential to the closure of
extracellular gates on the DAT, which mediates access to the substrate binding
sites (Cheng and Bahar, 2015; Malinauskaite et al., 2014). Therefore, it is
possible that mutation of this residue from a polar amino acid (Tyrosine) to a
hydrophobic one (Phenylalanine) slightly alters the local molecular environment
near the DA binding site, thus altering substrate binding kinetics. Consistent with
our in vitro reports, we did not demonstrate substantial differences in DAT
function or expression between Y88F and WT DAT mice. One exception
however is that we did not see the alterations in [ 3H]WIN 35,428 binding which
were observed in vitro. Although the human DAT (hDAT) and mouse DAT
(mDAT) display a high level of sequence homology (Donovan et al., 1995), since
our in vitro work utilized the hDAT, this discrepancy may be explained by the
small interspecies differences between the human and mouse transporters (Han
and Gu, 2006). Ultimately, the Y88F mutant DAT expressing mice demonstrate
normal transporter function/expression and locomotor activity, indicating that this
is a suitable model to examine the effects of HIV-1 Tat-mediated inhibition of
DAT in vivo.
Using a computational modeling and molecular dynamics approach, our
previous study (Midde et al., 2015) identified residues on the DAT which are
likely involved in the HIV-1 Tat/DAT interaction, one of which was Tyrosine88.
Specifically, it was predicted that the hydroxyl group on the Tyrosine88 side
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chain would form a hydrogen bond with nitrogen on the side chain of the
Lysine19 residue of HIV-1 Tat. Therefore, it was anticipated that mutation of the
Tyrosine88 residue of the DAT to a Phenylalanine, a structurally similar residue
to Tyrosine which lacks the para hydroxyl group, would weaken the interaction
between the two proteins, thereby preventing the associated inhibitory effects of
HIV-1 Tat on the DAT. Experimental validation confirmed this prediction,
confirming that Tyrosine88 on the DAT is a critical residue involved in the HIV-1
Tat/DAT interaction. In order to investigate if this interaction involved a similar
molecular mechanism in vivo, we performed [3H]DA uptake in the PFC and
striatum of iTat-tg/WT and iTat-tg/Y88F mice following 7-day treatment of both
genotypes with saline or Dox (Figure 4.3). First, we demonstrated that we were
able to replicate our previous findings (Strauss et al., 2020) demonstrating that
induction of HIV-1 Tat expression decreases the Vmax of [3H]DA uptake in the
PFC by ~30% in iTat-tg/WT mice, with no effect on Vmax in the striatum. However,
when we performed this same experiment in the iTat-tg/Y88F mice we did not
identify any alterations in the Vmax of [3H]DA uptake in the PFC or striatum. These
results demonstrate that HIV-1 Tat-mediated inhibition of DA uptake through the
DAT involves interactions between specific residues on these two proteins, and
furthermore, that a single point mutation on the DAT is capable of attenuating the
inhibitory effect by weakening the HIV-1 Tat/DAT molecular interaction.
Normal dopaminergic transmission is critical for maintenance of brain
activities involved in attention, learning, memory, and motivation (Nieoullon 2002;
Cools, 2006; Tye et al., 2013). Dysregulation of the dopaminergic system has
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been suggested to be a mediating factor in the development and progression of
HAND (Berger et al., 2000; Purohit et al., 2011; Gaskill et al., 2017), and several
studies have demonstrated that, even in the era of cART, HIV-1 infection alters
dopamine concentrations and metabolism in the brain (Kumar et al., 2009;
Scheller et al., 2010; Horn et al., 2013; Meulendyke et al., 2014). Furthermore,
previous studies have found that iTat-tg/WT mice display dopaminergic
dysregulation in the PFC (Strauss et al., 2020) and that these mice also exhibit
learning and memory deficits, as evidenced by their inability to successfully
perform the novel object recognition (NOR) task (Carey et al., 2012). We
hypothesized that attenuation of HIV-1 Tat-mediated inhibition of the DAT in
iTat-tg mice would prevent the reported deficits in NOR performance. While we
were able to replicate these reported deficits in NOR performance in the iTattg/WT mice (Carey et al., 2012), strikingly, the iTat-tg/Y88F did not exhibit any
decrease in NOR performance following induction of HIV-1 Tat expression.
Interestingly, our previous report (Strauss et al., 2020) demonstrated that HIV-1
Tat expression resulted in inhibition of not only DAT, but also the norepinephrine
transporter (NET). In the current study, we were able to demonstrate attenuation
of HIV-1 Tat-mediated inhibition of DA uptake through the DAT, but we did not
alter the HIV-1 Tat/NET interaction. This leads to the question of what the
respective impact of DAT versus NET inhibition is in the development of cognitive
deficits in HAND. The observed prevention of cognitive deficits associated with
the NOR task by only preventing the HIV-1 Tat/DAT interaction is likely due to
the respective roles of DAT versus NET in this specific behavioral test.
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Decreased DAT function has been linked with deficits in NOR performance
(Chang et al., 2018; Chang et al., 2020), whereas inhibition of NET function or
changes in PFC norepinephrine levels were not associated with altered NOR
performance (Carlini et al., 2012; Ray et al, 2019), but were associated with
deficits in the Y-maze. Thus it is possible that the observed prevention of
cognitive deficits identified in this study may be specific to the NOR task, and
furthermore performance of another behavioral test, such as Y-maze, may not
have demonstrated prevention of HIV-1 Tat-mediated cognitive deficits. In this
vein, future studies are warranted to determine the specific impact of DAT and
NET inhibition in the development of HAND pathology. Ultimately, our data
suggests that dopaminergic dysregulation mediated by the HIV-1 Tat/DAT plays
a significant role in the development of HAND pathology.
Taken together the current findings demonstrate that attenuation of the
HIV-1 Tat/DAT interaction via genetic manipulation of a single residue on the
DAT results in prevention of learning and memory deficits associated with HAND.
Although useful for research purposes, it is currently very difficult (and likely
unethical) to genetically modify human patients. In this vein it is critical to develop
novel therapeutic molecules which are capable of attenuating the HIV-1 Tat/DAT
interaction, without affecting normal transporter function. A recent report from our
laboratory (Sun et al., 2017) demonstrated that in vitro application of allosteric
modulators (SRI-20041 and SRI-30827) may prevent the inhibitory effects of
HIV-1 Tat on DAT function in vitro. Future studies investigating the use of these
compounds in iTat-tg mice to determine their ability to attenuate HIV-1 Tat-
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mediated dopaminergic dysregulation in vivo as well as on cognitive deficits
observed in this mouse model will be crucial to the progression towards a
preventative treatment for HAND.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
5.1 CONCLUSIONS
There are currently over 37 million people living with HIV-1 worldwide, and
another nearly 2 million becoming infected every year (HIV.gov). Even with the
success of cART, the majority of these patients continue to develop
neurocognitive deficits, substantially affecting their quality of life. Due to the
continued growth of the HIV-1 infected population, and because there currently
are no effective therapies for the treatment of HAND, it is estimated that the
number of HIV-1 patients with HAND will increase by 5- to 10-fold by the year
2030 (Cysique et al., 2011). A multitude of studies have suggested the continued
presence of the HIV-1 Tat protein in the CNS is a key mediator of the devasting
effects of HIV-1 infection (Koutsilieri et al., 2002b; Wang et al., 2004; Scheller et
al., 2005), particularly impacting the dopaminergic system (Gaskill et al., 2017;
Zhu et al., 2018). Several studies have indicated that the effects of HIV-1 Tat on
the dopaminergic system may be due to its interactions with the DAT (Midde et
al., 2013; Zhu et al., 2016; Yuan et al., 2016). As the DAT is a key regulator of
DA homeostasis in the CNS, HIV-1 Tat-mediated inhibition of transporter function
could potentially be linked to the dopaminergic dysregulation observed in HAND
patients, leading to neuropsychiatric dysfunction. This dissertation aimed to
elucidate the specific mechanisms by which HIV-1 Tat induces dysregulation of
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the dopaminergic system, and critically, what the impact of DA dysfunction has
on the development of HAND neuropathology and cognitive deficits.
This study demonstrated that biological expression of HIV-1 Tat in a
mouse model of HAND was sufficient to dysregulate the dopaminergic system.
Furthermore, this study identified, for the first time, that HIV-1 Tat is capable of
inhibiting not only the DAT but also the NET, both in vitro and in the PFC of HIV1 Tat expressing mice. These findings not only add to the current evidence that
HIV-1 Tat protein is a key mediator of dopaminergic dysregulation in HAND, but
additionally identified a novel mechanism underlying the neuropathological
abnormalities observed in this disorder.
Through the use of a mouse model which is capable of biological HIV-1
Tat expression and recapitulates the neuropathologies and neurocognitive
impairments evident in HAND (Kim et al., 2003; Carey et al., 2012) this study
was able to examine the impact of HIV-1 Tat-mediated inhibition of the DAT on
the development of HAND related cognitive deficits. It was determined that
attenuation of HIV-1 Tat-mediated inhibition of DAT in the PFC of iTat-tg mice via
a single point mutation on DAT (Y88F) was sufficient to prevent learning and
memory deficits which have previously been reported in this mouse model. This
finding identifies the HIV-1 Tat/DAT interaction as a realistic target for the
development of novel therapeutics to prevent the development of HAND.
5.2 FUTURE DIRECTIONS
While this dissertation provides key mechanistic insights into the
neuropathological developments of HAND, the development of these disorders is
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likely multifaceted, and thus future studies are warranted to investigate other
potential factors which may be involved. In this vein, a critical problem facing the
HIV-1 community is the disproportional amount of drug abuse in this population
(Norman et al., 2009). It has been demonstrated that drugs of abuse, particularly
cocaine and methamphetamine, can accelerate damage to the mesocorticolimbic
DA system in HIV-1 patients (Starace et al., 1998; Langford et al., 2003; Chana
et al., 2006; Meyer et al., 2014). Use of drugs of abuse in the HIV-1 population is
a double-edged sword, as their use increases the probability of contracting HIV1, or conversely, contracting HIV-1 increases the likelihood of drug abuse
(Soontornniyomkij et al., 2016). Because the DAT is involved in the
pharmacologic effects of both cocaine and methamphetamine, the mechanisms
underlying the synergistic effects of these drugs of abuse and HIV-1 viral proteins
may involve further effects on transporter function than those reported in this
dissertation. Thus, future investigation into the underlying mechanisms of these
synergistic effects, specifically with the HIV-1 Tat protein, may provide critical
information to prevent the devastating effects of these toxins.
This dissertation reported for the first time that the HIV-1 Tat protein is
capable of inhibiting DA uptake through the NET. As the HIV-1 Tat protein has
been found to interact with a variety of molecular targets within the CNS (King et
al., 2006), it is likely that additional pre-synaptic transporters involved in
monoaminergic regulation may be affected in HAND. Particularly, the vesicular
monoamine transporter (VMAT-2) has been previously found to be inhibited by
recombinant HIV-1 Tat protein in vitro (Midde et al., 2012). This previous report
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raises important questions. Can the inhibitory effects of HIV-1 Tat on VMAT-2
function be replicated in an animal model of HAND, and if so, does this
interaction involve a similar allosteric interaction as the identified interactions
between HIV-1 Tat and the DA and NE transporters? Furthermore, the VMAT-2
is also a target of drugs of abuse, specifically methamphetamine. Could the
synergistic effects of HIV-1 Tat and methamphetamine on the dopaminergic
system be mediated by combined effects on VMAT-2 function, expression or
localization? Answering these questions may further our mechanistic insight of
not only HAND neuropathology, but also mechanisms underlying neurocognitive
impairments resulting from methamphetamine abuse.
This dissertation has demonstrated that attenuation of HIV-1 Tat-mediated
inhibition of DAT function may be able to prevent some of the neurocognitive
impairments evident in HAND. Because there currently is no treatment to prevent
the development of HAND, it will be critical to develop novel therapeutic
molecules which are capable of attenuating the HIV-1 Tat/DAT interaction,
without affecting normal transporter function. Because the HIV-1 virus is capable
of penetrating the BBB and damaging the CNS shortly after initial infection,
ideally these therapies will be utilized in the early stages of HIV-1 infection.
Future studies investigating the use of novel small molecules to attenuate the
HIV-1 Tat/DAT and Tat/NET interactions and prevent HIV-1 Tat-mediated
dysregulation of the dopaminergic system will be invaluable to the improvement
of HIV-1 infected patients’ lives.
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Table A.1 Kinetic properties of [3H]DA uptake and [3H]WIN 35,428 binding for DAT in
C57BL/6J mice

Treatment duration

Prefrontal cortex

Striatum

Vmax
(pmol/min/mg)

Km (nM)

Vmax
(pmol/min/mg)

Km (nM)

7days

C57 - Saline

0.590 ± 0.080

90.8 ± 16

15.1 ± 1.1

100 ± 12

C57 - Dox

0.647 ± 0.044

77.6 ± 26

14.7 ± 1.2

103 ± 5.7

14days

C57 - Saline

0.685 ± 0.048

109 ± 10

51.9 ± 4.0

149 ± 7.5

C57 - Dox

0.708 ± 0.11

84.3 ± 8.3

54.7 ± 5.5

154 ± 8.2

Bmax
pmol/mg

Kd (nM)

Bmax
pmol/mg

Kd (nM)

C57 - Saline

0.423 ± 0.19

9.02 ± 1.3

26.9 ± 3.5

14.6 ± 0.89

C57 - Dox

0.395 ± 0.065

7.84 ± 1.5

29.9 ± 4.9

16.9 ± 2.1

7days

Data are expressed as mean ± S.E.M. values from five to seven independent
experiments performed in duplicate
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Table A.2 Kinetic properties of [3H]DA uptake and [3H]Nisoxetine binding for NET in
C57BL/6J mice

Treatment duration

Prefrontal cortex

Hippocampus

Vmax
(pmol/min/mg)

Km (nM)

Vmax
(pmol/min/mg)

Km (nM)

7days

C57 - Saline

1.15 ± 0.063

158 ± 42

0.972 ± 0.047

86.0 ± 16

C57 - Dox

1.14 ± 0.064

156 ± 35

0.962 ± 0.12

93.3 ± 18

14days

C57 - Saline

2.02 ± 0.25

92.2 ± 15

2.30 ± 0.29

86.5 ± 38

C57 - Dox

1.98 ± 0.24

83.9 ± 17

2.26 ± 0.22

88.9 ± 28

Bmax
pmol/mg

Kd (nM)

Bmax
pmol/mg

Kd (nM)

C57 - Saline

0.553 ± 0.051

12.9 ± 3.2

0.636 ± 0.11

7.39 ± 0.72

C57 - Dox

0.591 ± 0.12

11.0 ± 3.0

0.645 ± 0.13

8.59 ± 1.1

7days

Data are expressed as mean ± S.E.M. values from five to seven independent
experiments performed in duplicate.
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Table A.3 Kinetic properties of [3H]DA uptake via DAT in PFC and striatum or NET in
PFC and hippocampus in G-tg mice following 7-day administration of saline or Dox
Prefrontal cortex

DAT

Vmax
(pmol/min/mg)

Km (nM)

Vmax
(pmol/min/mg)

Km (nM)

G-tg Saline

0.343 ± 0.037

61.0 ± 18

33.3 ± 4.7

78.1 ± 5.3

G-tg - Dox

0.317 ± 0.065

55.5 ± 17

32.3 ± 2.7

73.1 ± 1.4

Prefrontal cortex

NET

Striatum

Hippocampus

Vmax
(pmol/min/mg)

Km (nM)

Vmax
(pmol/min/mg)

Km (nM)

G-tg Saline

0.945 ± 0.058

89.3 ± 23

1.39 ± 0.13

110 ± 10

G-tg - Dox

1.09 ± 0.20

75.7 ± 2.5

1.41 ± 0.10

113 ± 23

Data are expressed as mean ± S.E.M. values from three independent
experiments performed in duplicate.
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Table A.4 Average age and total number of mice used for each experiment type by
genotype and treatment.
iTat-tg
Saline

iTat-tg
Dox

C57
Saline

C57
Dox

Total mice
used

11.3 ± 0.41 10.8 ± 0.30

11.8 ± 0.11

12.0 ± 0.09

168

14-day [ H]DA
uptake

11.8 ± 0.34 11.2 ± 0.26

11.4 ± 0.24

11.4 ± 0.24

144

Surface Biotinylation

11.1 ± 0.14 11.1 ± 0.14

10.9 ± 0.15

10.9 ± 0.15

36

10.6 ± 0.28 10.3 ± 0.19

12.0 ± 0.27

12.0 ± 0.27

120

11.9 ± 0.17 11.9 ± 0.17

12.6 ± 0.21

12.6 ± 0.21

24

10.3 ± 0.44 10.4 ± 0.23

10.6 ± 0.30

11.0 ± 0.25

12

7-day [3H]DA uptake
3

3

[ H]WIN and
[3H]NXT binding
DA and DOPAC
tissue content
Patch Clamp Ephys.

Age of mice is shown in weeks ± S.E.M.. Note that for several experiments the saline
and dox groups are exactly the same age; this is because they were tested
simultaneously, and treatment was able to be distributed amongst littermates in
these experiments.
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Table A.5 Pearson’s correlation coefficient of age versus experimental output
PFC – DAT

STR – DAT

PFC – NET

HIP – NET

0.018

0.031

0.273

0.018

0.024

0.216

0.345

0.260

Total

-0.433

-0.101

-0.048

-0.516

Surface

-0.258

-0.040

-0.200

0.193

[3H]WIN and [3H]NXT
binding (Bmax)

-0.166

0.445

-0.020

0.423

PFC – DA

PFC –
DOPAC

STR – DA

STR – DOPAC

7-day [3H]DA uptake
(Vmax)
14-day [3H]DA uptake
(Vmax)
Biotinylation

DA and DOPAC
-0.365
-0.166
-0.275
0.192
tissue content
Pearson’s correlation coefficient was determined using Graphpad Prism 8 software.
Age was used as the x-axis and experimental output was used for the y-axis. No
significant correlations were found between age and any experimental output.
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Figure A.1 Analysis of plasmalemmal surface expression of DAT and NET was
determined in the striatum and hippocampus of iTat-tg mice following 7-day
administration of saline or Dox. Synaptosomes were incubated with sulfo-NHSbiotin and Pierce monomeric avidin beads and washed multiple times to isolate
the DAT or NET which was present on the plasmalemmal membrane. Top
panels: representative immunoblots of the total and biotinylated (Biotin) fraction
of DAT in the striatum (A) or NET in hippocampus (B) from iTat-tg mice from
Dox-treated and saline (SAL) control groups. Calnexin was used as control
protein. Bottom panels: the ratio of total or biotinylated DAT (A) and NET (B)
immunoreactivity to calnexin immunoreactivity expressed as mean ± S.E.M. from
five independent experiments.
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Figure A.2 Analysis of plasmalemmal surface expression of DAT (in PFC and
striatum) and NET (in PFC and hippocampus) was determined in C57BL/6J mice
following 7-day administration of saline or Dox. Synaptosomes were incubated
with sulfo-NHS-biotin and Pierce monomeric avidin beads and washed multiple
times to isolate the DAT or NET which was present on the plasmalemmal
membrane. Top panels: representative immunoblots for the total and biotinylated
(Biotin) fraction of DAT in the PFC (A) and striatum (C) or NET in the PFC (B)
and hippocampus (D) from C57BL/6J (C57) from Dox-treated and saline (SAL)
control groups. Calnexin was used as control protein. Bottom panels: the ratio of
total or biotinylated DAT or NET immunoreactivity to calnexin immunoreactivity
(A-D) expressed as mean ± S.E.M. from 3-5 independent experiments.
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Figure A.3 DA and dihydroxyphenylacetic acid (DOPAC) tissue content in the
PFC and striatum of G-tg mice following 7-day administration of saline or Dox.
Top panels: DA (A) and DOPAC (B) tissue content in the PFC of G-tg mice from
Dox-treated or saline (SAL) control groups. Bottom panels: DA (C) and DOPAC
(D) tissue content in striatum (STR) of G-tg mice from Dox-treated or saline
(SAL) control groups. Data are expressed as ng/mg tissue (mean ± S.E.M.) from
5-6 independent experiments.
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Figure A.4 Whole-cell patch clamp electrophysiology was performed in layer V
pyramidal neurons of the prelimbic region of PFC in C57BL/6J mice following 7day administration of saline or Dox. Coronal slices (300 µm) containing the
prelimbic cortex were cut with a Vibratome and incubated in an ice-cold artificial
CSF (aCSF) solution at 32–34°C for 45 min and kept at 22–25°C thereafter, until
transfer to the recording chamber. (A) Representative traces from C57BL/6J
(C57) mice treated with saline (C57-Saline) and Dox (C57-Dox) following
hyperpolarizing (-200 pA) and depolarizing (+200 pA) current steps. Summary of
basal action potential frequency (B) and action potential frequency in response to
acute application of DA (10 nM) or DA + GBR 12909 (100 nM) or DA + GBR
12909 + DMI (1 µM) of neurons from C57BL/6J mice treated with saline (C) or
Dox (D).
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Figure A.5 Representative immunoblots for total DAT (A), NET (B), and Calnexin
(C) in C57 or iTat mice treated with saline or dox. Total and intracellular DAT (A),
NET (B), and Calnexin (C) expression in C57 and iTat mice following 7-days of
saline or dox treatment. The total and intracellular fractions were prepared and
loaded as described in the methods section under the biotinylation and western
blot heading. The membrane was first probed using the C-20 anti-DAT antibody
(A), then stripped using RestoreTM Western Blot Stripping Buffer (ThermoFisher,
cat# 21059), and re-probed with NET05-1 anti-NET antibody (B). The same
membrane was then stripped again and re-probed with H70 anti-calnexin
antibody (C) to monitor protein loading between all lanes. Lanes C and D from
panel A are shown in Figure 3.2A as total DAT fraction, and lanes C and D from
panel B are shown in Figure 3.2B as total NET fraction. Lanes C and D from
panel C are shown as the loading control for both total DAT (Figure 3.2A) and
NET (Figure 3.2B) as the same sample was used to determine the expression of
both proteins. Lanes A and B from all panels were used in Figure A.2A and A.2B
in an identical manner.
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Figure A.6 Representative immunoblots for biotinylated DAT (A), NET (B), and
Calnexin (C) in C57 or iTat mice treated with saline or dox. Biotinylated DAT (A),
NET (B), and Calnexin (C) expression in C57 and iTat mice following 7-days of
saline or dox treatment. The biotinylated fraction was prepared and loaded as
described in the methods section under the biotinylation and western blot
heading. The membrane was first probed using the C-20 anti-DAT antibody (A),
then stripped using RestoreTM Western Blot Stripping Buffer (ThermoFisher, cat#
21059), and re-probed with NET05-1 anti-NET antibody (B). The same
membrane was then stripped again and re-probed with H70 anti-calnexin
antibody (C) to monitor protein loading between all lanes. Lanes C and D from
panel A are shown in Figure 3.2A as biotinylated DAT fraction, and lanes C and
D from panel B are shown in Figure 3.2B as biotinylated NET fraction. Lanes C
and D from panel C are shown as the loading control for both biotinylated DAT
(Figure 3.2A) and NET (Figure 3.2B) as the same sample was used to determine
the expression of both proteins. Lanes A and B from all panels were used in
Figure A.2A and A.2B in an identical manner.
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